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 ABSTRACT 
 
Introduction: This thesis aims to characterize the biology of solid and liquid 
phase coronary thromboaspirate obtained during therapeutic aspiration at primary 
angioplasty for ST elevation myocardial infarction (STEMI).  
Methods: We studied coronary thromboaspirate obtained from the coronary artery 
(CA) in STEMI and focussed on three lines of investigation:  
• Intracoronary solid phase thrombus was subjected to immunohistochemistry 
for characterization and quantification of the different leukocyte types and proteins 
involved in the thrombus.  
• Resident cell populations in the liquid phase filtrate from the aspirate including 
platelets and leukocytes along with their subpopulations were analysed by flow 
cytometry for phenotypic and activation markers. Comparison was made with cells 
in the peripheral femoral artery (FA) blood.  
• Paired plasma/serum from the CA filtrate and FA blood were analysed for the 
presence of autoreactive antibodies and cytotoxic potential.  
 Results:  
• Leukocytes were heterogeneously distributed in the ex-vivo thrombus. The 
granulocyte population was predominant and strongly expressed CD11b and 
vimentin.  
• The CA aspirate filtrate when compared to the paired FA blood contained 
significantly more leukocyte-platelet conjugates, more activated platelets, and 
more Vimentin.  
• More of the CD4+ T cells in the CA than FA had lost the co-stimulatory 
molecule CD28 (p<0.00001) and they often expressed effector phenotype marker. 
• Conversely, the immune-regulatory T cells expressing the FoxP3 were more 
attenuated in the CA than FA (p<0.00001).  
• Whilst IgG and IgM antivimentin antibody titres in the CA sera were 
consistently lower than the titres in FA sera (p<0.001), auto-reactive non-HLA IgM 
were more prevalent in CA sera. The CA sera had increased potential to induce 
apoptosis than FA sera when incubated with endothelial cells (p<0.001).     
Conclusions:   
• Aspirated intracoronary clot contained granulocytes as the predominant 
leukocyte component. This investigation of the immune system in the CA during 
AMI therefore moved on to the adaptive system in the coronary filtrate.  
• Increased concentrations of pro-inflammatory immune cells and reduced 
concentrations of immune-modulating cells were observed in the aspirate from the 
culprit site of CA occlusion when compared with the FA. The presence of T 
memory cells implies that this subset may have been released from the ruptured 
coronary plaque and this phenotypic analysis may help clarify the role of the 
immune system in the pathogenesis of coronary plaque instability.  
• The higher titres of auto-reactive IGM in the CA than FA sera have the 
potential to activate the complement system and may contribute to myocardial 
injury following therapeutic restoration of coronary flow in STEMI.   
 
 
4
 TABLE OF CONTENTS 
 
 
DEDICATION .............................................................................................2 
PRESENTATIONS AND PUBLICATIONS.................................................3 
ABSTRACT................................................................................................4 
GLOSSARY OF ABBREVIATIONS...........................................................8 
ETHICAL CONSIDERATIONS...................................................................9 
PARTICIPANTS .......................................................................................10 
ACKNOWLEDGEMENTS ........................................................................11 
CHAPTER 1: INTRODUCTION................................................................13 
AIMS OF THIS THESIS ...................................................................................13 
BACKGROUND.............................................................................................13 
1.2. HISTORICAL PERSPECTIVE.....................................................................14 
1.3. ACUTE CORONARY SYNDROMES ............................................................16 
1.4. THROMBUS ARCHITECTURE...................................................................18 
1.5. T CELL DEVELOPMENT .........................................................................19 
1.6. RECIRCULATION OF NAÏVE T CELLS ........................................................20 
1.7. DEVELOPMENT OF MEMORY T CELLS .....................................................22 
1.8. RECIRCULATION OF MEMORY T CELLS ....................................................22 
1.9. THE ROLE OF IMMUNE CELLS IN ATHEROSCLEROSIS .................................24 
1.10.  HYPOTHESIS FOR THIS THESIS ............................................................38 
1.11.  OUTLINE PLAN OF INVESTIGATION........................................................38 
1.12 GENERAL STATISTICAL AND SAMPLE SIZE CONSIDERATIONS.....................39 
CHAPTER 2: METHODS AND MATERIALS...........................................40 
2.1. RECRUITMENT OF TEST COHORT............................................................40 
2.2. RECRUITMENT OF CONTROL COHORT .....................................................41 
2.3. CLINICAL CHARACTERISTICS .................................................................42 
2.4. PLAN OF INVESTIGATIONS......................................................................43 
2.5. SAMPLE COLLECTION............................................................................43 
2.6. SAMPLE PROCESSING ...........................................................................46 
2.7. FLOW CYTOMETRY ...............................................................................49 
2.8. INVESTIGATION OF POTENTIAL CONFOUNDING FACTORS ...........................52 
2.9. STATISTICAL CONSIDERATIONS ..............................................................55 
CHAPTER 3:  SOLID PHASE CORONARY THROMBUS ......................57 
3.1. BACKGROUND......................................................................................57 
3.2. METHOD..............................................................................................58 
3.3. RESULTS .............................................................................................59 
3.4. CONCLUSION .......................................................................................64 
 
 
5
CHAPTER 4: LIQUID PHASE- PLATELETS AND PLATELET LEUKOCYTE 
CONJUGATES.........................................................................................65 
4.1. BACKGROUND......................................................................................65 
4.2. METHOD..............................................................................................66 
4.3. RESULTS .............................................................................................71 
4.4. CONCLUSION .......................................................................................79 
CHAPTER 5: LIQUID PHASE –ACTIVATED, PROINFLAMMATORY AND 
REGULATORY T LYMPHOCYTES .........................................................81 
5.1. BACKGROUND......................................................................................81 
5.2. METHOD..............................................................................................82 
5.3. RESULTS .............................................................................................87 
5.4.  CONCLUSION ......................................................................................93 
CHAPTER 6:  LIQUID PHASE- REACTIVE ANTIBODIES .....................96 
6.1. BACKGROUND......................................................................................96 
6.2. METHOD..............................................................................................96 
6.3. RESULTS ...........................................................................................101 
6.4. 4. CONCLUSION..................................................................................104 
CHAPTER 7:  VIMENTIN AND ANTIVIMENTIN ANTIBODIES.............106 
7.1 BACKGROUND.....................................................................................106 
7.2 METHODS: ELISA FOR ANTIVIMENTIN ANTIBODIES .................................106 
7.3 RESULTS ............................................................................................108 
7.4 CONCLUSIONS ....................................................................................109 
CHAPTER 8:  LIQUID PHASE- CYTOTOXICITY AGAINST ENDOTHELIAL 
CELLS....................................................................................................111 
8.1. BACKGROUND....................................................................................111 
8.2. METHODS..........................................................................................111 
8.3. RESULTS ...........................................................................................112 
8.4. CONCLUSION .....................................................................................116 
CHAPTER 9: CONCLUSIONS...............................................................117 
9.1. RATIONALE AND PLAN OF INVESTIGATION..............................................117 
9.2. SPECIFIC FINDINGS OF THE INVESTIGATIONS .........................................118 
9.3. STUDY LIMITATIONS............................................................................124 
9.4. FUTURE DIRECTIONS...........................................................................125 
CHAPTER 10: REFERENCES...............................................................127 
 
 
 
6
TABLE OF FIGURES 
 
 
 
Figure 1.1: Intracoronary thrombus 17 
Figure 1.2: T-cell margination 21 
Figure 1.3: T-cell memory subtypes 23 
Figure 2.2: Thrombus aspiration catheter 45 
Figure 2.3: Ex vivo intra-coronary thrombus from patient with STEMI 45 
Figure 2.4: Whole blood preparation for flow cytometry 47 
Figure 2.5: Whole blood FACS after red cell lysis using FSC and SSC 50 
Figure 2.6: Absorption and emission fluorochrome spectra 51 
Figure 2.7: Controlling for contrast media effect 54 
Figure 3.1: Illustration of thrombus orientation 57 
Figure 3.2: Ex-vivo coronary thrombus & platelet-fibrin heterogeneity 60 
Figure 3.3: Ex vivo coronary thrombus 61 
Figure 3.4: Cell types in thrombus 62 
Figure 3.5: Vimentin expression 63 
Figure 4.1: Co-localization of mono-nucleated white blood cells 68 
Figure 4.2: Controlling for contrast media 70 
Figure 4.3: Comparison of platelet activation markers 72 
Figure 4.4: Total platelet leukocyte conjugates 73 
Figure 4.5: Platelet monocyte conjugates (FACS) 74 
Figure 4.6: Platelet monocyte conjugates (summary) 75 
Figure 4.7:  Lymphocyte-platelet conjugates (FACS) 77 
Figure 4.8: Platelet lymphocyte conjugates (Summary) 78 
Figure 4.9: Time and lymphocyte platelet conjugates 79 
Figure 5.1: Multichannel multicolour flow cytometry for CD4+ CD28null T lymphocytes
 85 
Figure 5.2: Intracytoplasmic flow cytometry 87 
Figure 5.3: Activated T-Lymphocytes in STEMI 88 
Figure 5.4: Proinflammatory (CD4+ CD 28 null) Lymphocytes 90 
Figure 5.5: CD4+ CD28null cells expressing memory T cell marker CD45RO. 91 
Figure 5.6: Phenotypic subanalysis of the CD4+ CD28null memory T (CD45RO+) 
lymphocytes 92 
Figure 5.7: Immunoregulatory FOXP3 expression 93 
Figure 6.1: Terasaki plate 98 
Figure 6.2 Cell viability 99 
Figure 7.1: ELISA plate 107 
Figure 8.1a Apoptotic cells 113 
Figure 8.1 Cytotoxicity against endothelial cells 113 
Figure 8.2: Time course of endothelial cell apoptosis 115 
Figure 8.3: Endothelial cell viability at 24 hours 116 
 
 
 
7
 GLOSSARY OF ABBREVIATIONS 
 
 
ACS:    Acute Coronary Syndrome 
(A)MI:  (Acute) Myocardial Infarction 
APC:   Allophycocyanin 
CCR:   Chemokine Receptor
CD:     Cluster of Differentiation 
CHD:  Coronary Heart Disease 
CSA:  Chronic Stable Angina 
FITC:  Fluorescein Isothiocyanate 
FSC:   Forward Scatter 
HLA:   Human Leukocyte Antigen 
HSP:  Heat Shock Protein 
IL:       Interleukin 
Ig:       Immunoglobulin 
MHC:  Major Histocompatibility Complex 
NCA:  Normal Coronary Artery 
NSTEMI: Non ST Elevation Myocardial Infarction 
PBS:  Physiological Buffer Saline 
PCI:    Percutaneous Coronary Intervention 
PE:     Phycoerythrin 
PPCI: Primary Percutaneous Coronary Intervention 
SSC:  Side Scatter 
SD:     Standard Deviation 
TCR:  T Cell Receptor 
TCM:  Central Memory T cell 
TEM:  Effector Memory T cell 
 
 
  
 
 
 
8
ETHICAL CONSIDERATIONS 
 
The local ethics committee at Royal Brompton and Harefield NHS Trust had 
prospectively approved all of the work within this thesis. Written informed consent 
was obtained from all participants. Data obtained from subjects enrolled into the 
following two research studies were used in this thesis: 
 
1. An Investigation into the Mechanisms of Thromblytic Resistance: COREC 
reference number: 06/Q0404/58 
2. Percutaneous Coronary Intervention as a model of clinical inflammation: 
COREC reference number: 06/Q0404/55 
 
 
 
 
 
 
 
 
 
 
9
 PARTICIPANTS 
 
 
With the supervision of Dr M C D Dalby, Dr R K Kharbanda and Professor M. 
Rose all the study designs, ethical committee submissions, recruitment of 
subjects, sample collections, sample preparation and processing, flow cytometric 
and immunohistochemistry work was performed by Dr G Ghimire.  All the studies 
were performed within the premises of Royal Brompton and Harefield NHS Trust 
and the Harefield Heart Science centre, Imperial College London.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10
ACKNOWLEDGEMENTS 
 
 
 
 
Dr Miles Dalby: Consultant Interventional Cardiologist, Royal Brompton and 
Harefield NHS Trust, for continual help and support throughout the work of this 
thesis.  
Dr Rajesh Kharbanda: Consultant Interventional Cardiologist, Royal Brompton 
and Harefield NHS Trust, for guidance, support and help with this thesis. 
Professor Marlene Rose: Transplant Immunology, Imperial College, for the 
guidance, encouragement and supervision.   
Dr Ranil DeSilva: Consultant Interventional Cardiologist, Royal Brompton and 
Harefield NHS Trust, for mentoring, guidance, support and help with this thesis. 
Ann McCormack: Harefield Heart Science Centre, Imperial College, for all the 
technical and scientific guidance and help with the endothelial cell project.  
Dr John Smith: Transplant Immunologist, RBHT, for all the help for the 
autoantibody screening and AVA testing. 
Dr Jonathan Spiro: Interventional Cardiology Research Fellow Royal Brompton 
and Harefield NHS trust, for constant support through the uncertain times.  
Dr Charles Ilsley:  Consultant Interventional Cardiologist, Royal Brompton and 
Harefield NHS Trust for providing with the intracoronary and femoral arterial 
samples.   
Dr Mark Mason: Consultant Interventional Cardiologist, Royal Brompton and 
Harefield NHS Trust for providing all the support and for obtaining the 
intracoronary and femoral arterial samples. 
 
 
11
Dr Andrew Mitchell Consultant Interventional Cardiologist, Royal Brompton and 
Harefield NHS Trust for providing with the intracoronary and femoral arterial 
samples. 
Michael Roughton: Statistician, Royal Brompton and Harefield NHS Trust for 
helping with all the statistical work.  
Dr Phil Moore:  Cardiology Specialist Registrar, Royal Brompton and Harefield 
NHS Trust for providing with the intracoronary and femoral arterial samples. 
Dr Rebecca Lane: Cardiology Specialist Registrar, Royal Brompton and Harefield 
NHS Trust for providing with the intracoronary and femoral arterial samples. 
 
 
 
12
CHAPTER 1: INTRODUCTION 
 
 
Aims of this thesis 
 
This thesis concerns analysis of the cellular and immunological characteristics of 
coronary thromboaspirate obtained at primary angioplasty (PPCI) for acute ST 
elevation myocardial infarction (STEMI) and comparison with femoral artery blood 
of the same subject as well as with patients with stable coronary artery disease. It 
addresses the cellular composition of the particulate thrombus, the characteristics 
of the resident cellular component of the aspirate, and finally the toxic potential of 
the serum component of the aspirate. The significance of this investigation is two 
fold: firstly it may allow insight into the pathogenesis of the plaque rupture and 
coronary occlusion process. Secondly it may allow identification of potentially 
cytotoxic factors which may contribute to the phenomenon of distal myocardial 
damage often occurring with the therapeutic restoration of coronary flow in STEMI. 
Background 
Atherosclerotic coronary artery disease continues to be accountable for a 
significant portion of morbidity and mortality in developed countries despite 
significant improvement in available therapeutic options. Our understanding of the 
pathology of this condition is largely based on studies on animal models and post-
mortem series; but both methods have significant inherent limitations.  
Primary percutaneous intervention (PPCI) for acute ST elevation myocardial 
infarction (STEMI) is now firmly established as the preferred therapeutic modality 
to restore the coronary perfusion.1,2 An increasing body of evidence favours 
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aspiration thrombectomy as an adjunct to PPCI.3 This procedure not only appears 
to improve clinical outcome but also provides a unique opportunity during which 
athero-thrombotic material can be directly aspirated from the culprit site of the 
infract related artery and subjected to scientific investigation. A detailed analysis of 
this ex-vivo specimen may provide novel insights in to the dynamics of plaque 
instability.  
1.2. Historical perspective 
Atherosclerosis 
The term ‘‘atheroma’’ is derived from Greek ‘‘athera’’ (gruel) and was originally 
applied to describe a plaque with central yellow lipid core.  Although this 
nomenclature is relatively young, its corresponding entity stretches to antiquity 
and had been described in mummies of 18th dynasty of the pharaohs of Egypt.4  
The theory of pathogenesis of atherosclerosis has evolved over the last 160 
years. In 1844 von Rokitansky proposed the ‘‘encrustation’’ hypothesis proposing 
that atheroma is derived from healing and resorption of organised mural 
thrombus.5 Rudolf Virchow in 1856 refuted this hypothesis by observing that the 
localised intimal thickening was subendothelial and proposed his infiltrative theory 
that plasma components (including lipids) elicited an inflammatory response in the 
arterial wall.6 This idea was subsequently modified by Antischkow and further 
included the role of platelets and thrombosis in atherosclerosis.7 Although Duguid 
transiently revived the thrombogenic aetiology of atherosclerosis,8,9 the lipid 
deposition and inflammation hypothesis became more widely accepted.  John 
French subsequently reported the critical role of structural integrity of endothelial 
lining in maintaining normal vasomotion and its alteration leading to genesis of 
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atherosclerosis.10 On the basis of their observations on hypercholesterolemic 
animals, Ross and Glomset proposed that injury to the endothelium was the 
initiating event in atherogenesis11 and Ross updated his theory a decade later.12  
Atherosclerosis is now considered a chronic inflammatory and proliferative 
condition which in essence is a response to chronic injury inflicted by noxious 
stimuli such as chronic hypercholesterolemia,13 shear stress due to 
hypertension,14 potentially microbes,15,16 and other toxins.17 This involves 
interactions between various cell lines including endothelial cells, macrophages, 
smooth muscle cells, platelets and lymphocytes. 18,19,20  
Myocardial Infarction 
In 1892 Sir William Osler, on the basis of post-mortem studies, described the 
underlying cause of acute myocardial infarction as “The blocking of one of these 
vessels by a thrombus or an embolus leads to a condition which is known as 
anaemic necrosis, or white infarct. This is most commonly seen in the left ventricle 
and in the septum, in the territory of distribution of the anterior coronary artery.”21 
The then prevalent concept that acute myocardial infarction was inevitably a fatal 
condition was challenged by George Dock when he described  the diagnosis of 
myocardial infarction in a live patient in his paper, `Notes on the coronary 
arteries`, published in 1896.22  Subsequently, in a presentation to the Association 
of American Physicians in 1912, James Herrick correlated the classic signs and 
symptoms of acute myocardial infarction with acute coronary artery occlusion,23  
refuted the concept that acute myocardial infarction is invariable a fatal condition 
and made the term coronary thrombosis almost synonymous with acute 
myocardial infarction. However over the next half a century the cardiology 
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community was embroiled over the controversy that the coronary thrombosis may 
be the effect of acute myocardial infarction rather than the cause of it. This 
controversy began with the publication of a paper by Friedberg and Horn in 1939 
24 who observed coronary thrombosis in only 31% of patients who had evidence of 
myocardial necrosis on autopsy. They also noted that some patients with classic 
clinical and electrocardiographic signs of MI had evidence of coronary thrombosis, 
while others did not. The central role of the thrombus formation in pathogenesis of 
acute myocardial infarction was unequivocally established by the angiographic 
studies performed during the first hours of the acute events by De wood et al who 
demonstrated that 87 percent of patients with acute myocardial infarction within 4 
hours had thrombotic occlusion, with the percentage falling to 65 percent when 
patients were studied 12 to 24 hr after onset of chest pain.25 The decreasing 
frequency of thrombi over time is probably explained by endogenous fibrinolysis, 
fragmentation and distal embolisation with infarct evolution. 
1.3. Acute coronary syndromes 
Quantitative morphometric studies have shown that despite progressive growth of 
an atherosclerotic plaque, luminal narrowing and flow limitation does not occur 
until the plaque occupies about 40% of the space limited by the internal elastic 
lamina due to initial positive remodelling.26 Angiographic studies have shown that 
the subsequent progression is unpredictable and phasic rather than linear with 
time.27 This non-linearity is due intermittent plaque inflammation with consequent 
disruption leading to superimposed thrombosis and subsequent spontaneous 
healing. Such phasic episodes may remain asymptomatic if there is no limitation 
of blood flow or may manifest as unstable angina if there is subtotal thrombotic 
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occlusion of the coronary artery or as acute myocardial infarction if there is 
complete thrombotic occlusion of the coronary artery. 28 
 
 
 
 
 
 
 
 
 
Human coronary atherosclerotic plaque with a yellow core of lipid separated from the lumen by a fibrous cap 
 
 
                                     
                 
 
 
                
Intramural non-occlusive thrombus                                                            Occlusive intra-coronary thrombus              
Unstable Angina                                                                                       Acute Myocardial Infarction 
Figure 1.1: Intracoronary thrombus 
Davies M .Stability and Instability: Two Faces of Coronary Atherosclerosis Circulation. 1996; 94:2013-2020. 
 
Angiographic,29,30,31 angioscopic,32 and atherectomy33 studies had consistently 
demonstrated the presence of intracoronary thrombus in the majority of patients 
with unstable acute coronary syndromes (figure 1.1).  Retrospective analysis of 
angiograms performed at variable interval before the index acute coronary 
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syndrome has indicated that the majority of ACS results from rupture of non-flow 
limiting intermediate coronary lesions.34,35 Data from necropsy studies of patients 
who succumb to acute coronary events suggest plaque composition to be the key 
determinant of the propensity of the atherosclerotic lesion to rupture and provoke 
clinical events. The culprit lesions are typically eccentric, thin capped 
fibroatheroma with large avascular and hypocellular, necrotic lipid core.36,37,38 
Multiple factors may contribute to transformation of the stable plaque into the 
rupture prone unstable lesion however increasing evidence supports the role of 
immune cells particularly T lymphocytes in this destabilizing process.  
1.4. Thrombus Architecture 
Formation of thrombus on disrupted atherosclerotic plaques is the fundamental 
event in the development of acute coronary syndromes and in the progression of 
atherosclerosis.39 The basic component of the thrombus includes polymeric 
scaffolds of fibrin and enmeshed platelets, erythrocytes and leukocytes. However, 
published data on the proportional composition of these components is quite 
variable.  One necropsy study showed that only 15% of occlusions consist of pure 
platelet thrombus, whereas 85% of occlusive thrombi are largely composed of 
fibrin as well as platelets;40 another study found that all of the thrombi detected at 
plaque disruption sites consisted of a mixture of fibrin and platelets.41  Similarly, 
fibrin appear to be more abundant than platelets in thrombi on ruptured plaques, 
while thrombi on eroded plaques were relatively richer in platelets than in fibrin. 
Anatomically, it has been suggested that the right coronary artery possesses 
thrombi that are richer in erythrocytes than in thrombi from the left coronary 
artery.42 There is significant morphological heterogeneity within a thrombus due to 
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polarity of distribution of platelets and erythrocytes. The platelets cluster on the 
“head end” which is in continuity with the plaque crater while the tail end is chiefly 
composed of erythrocytes and fibrin. Histopathological findings and imaging and 
experimental studies have highlighted the important role of leukocytes that are 
actively recruited into growing, platelet-rich arterial thrombi.43  All thrombi 
continually undergo propagation, organization, embolisation, lysis, and re-
thrombosis, and this dynamic remodelling results in constantly changing 
compositions.  
1.5. T Cell Development 
 
T lymphocytes are derived from CD7+ T cell progenitors which arise from the bone 
marrow from multi-potential lymphoid stem cells.44,45  The progenitor cells then 
migrate to the thymus.46 Approximately 50-100 progenitor cells enter the thymus 
daily.47 This trafficking is a coordinated process orchestrated by various cell 
adhesion molecules, chemokines and cytokines.48  In the thymus the T cells 
rearrange pairs of genes that encode for the heterodimeric T cell Receptor (αβ or 
γδ) and express it in association with the CD3 complex. At this stage the cells are 
CD4+ CD8+ and engage antigen –MHC complexes on thymic epithelium or 
dendritic cells. The clone of cells expressing TCR that have low affinity with the 
antigens is positively selected, whilst those exhibiting high or no affinity are 
selectively eliminated by apoptosis. T cells bearing TCR that recognize MHC class 
I maintain CD8 expression, down regulate CD4 expression and become CD8+ T 
cells. Conversely, T cells bearing TCR that recognize MHC class II become CD4+ 
T cells.  Only 3% of the immature thymocytes survive the gene rearrangement and 
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the selection process. These naïve T cells reside in the thymic medulla for 12-14 
days before migrating to the periphery.  
1.6. Recirculation of naïve T cells 
 
 The circulation of the naïve T cell circulation is essential for host surveillance.  
They constitutively migrate to the secondary lymphoid organs where there is 
maximum probability of encountering its cognate antigen presented on the MHC 
complex of the APCs. In the lymphoid tissue the T cells extravasate preferentially 
through high endothelial venules. If they do not encounter any antigen for which 
they bear specific receptor they re-circulate back to the blood via the efferent 
lymph.49  
The leukocyte-endothelial cell interaction during the extrvasation cascade is 
defined in a multistep paradigm50,51 which comprises of:  
1.6.1. Rolling 
The lymphocytes marginate out of the main bloodstream and begin to tether and 
roll on the surface of the endothelium. In peripheral lymph nodes this is mediated 
by interaction between L-selectin (CD62L) expressed on the naïve lymphocytes 
and sulphated sialyl-lewisx –like sugars which are  called peripheral node 
addressin (PNAd) in high endothelial venules and CD34.52 The naïve T cell 
migration to gut-associated lymphoid tissue, on the other hand, is mediated by 
LPAM-1(α4β7) and mucosal addressin-cell adhesion molecule type 1 (MAdCAM-
1).    
1.6.2. Activation and firm adhesion 
The rolling naïve lymphocytes are exposed to the homeostatic chemokines CCL19 
and CCL 21 expressed on the surface of the high endothelial venules53,54 which 
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bind to the G-protein coupled receptor CCR7 expressed on the naïve 
lymphocytes. This interaction activates the lymphocytes inducing conformational 
changes that increase ligand affinity of the lymphocyte integrin without changing 
its density which in turn mediate firm adhesion to the endothelium. The integrins 
are transmembrane molecules composed of noncovalently associated α and β 
dimers. The integrins expressed on the naive lymphocyte and their cognate 
ligands expressed on endothelium includes lymphocyte function-associated 
antigen-1 (LFA-1, αLβ2) and intracellular cell adhesion molecule (ICAM-1,2,3),55, 
56,57 very late antigen-4 (VLA-4, α4β1) and vascular cell adhesion molecule-1 
(VCAM-1),58 α4β7 and MadCAM,59 and αEβ7 and E-cadherin.60 
                                     
 
Figure 1.2: T-cell margination 
1.6.3. Extravasation  
Finally the lymphocyte emigrates through the endothelial cell junction 
(paracellelular route)61 although transmigration of the neutrophils through the 
transcellular route has been observed.62 The molecular mechanism involved in 
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the transmigration includes CD31 (platelet endothelial cell adhesion molecule-, 
PECAM-1), junctional adhesion molecules (JAM A, B and C), CD99 and 
endothelial cell-selective adhesion molecule (ESAM). 
1.7. Development of Memory T cells 
Upon recognition of antigenic peptides on APC naïve T lymphocytes proliferate 
and differentiate in to a variety of effector cells depending on the stimulatory 
condition and the cytokine milieu.63  A fraction of the primed T cells persists as 
dynamic repository of antigen experienced memory T lymphocyte that on 
secondary encounter with the specific antigen produce a qualitatively different and 
quantitatively augmented response.64,65 The naïve and the memory T cells can be 
identified by the reciprocal expression of the CD45 RA and CD45RO isoforms.66 
On the basis of expression of homing receptor CCR7 and CD62L, the memory T 
cells can be defined in to two distinct subsets.67,68 The CCR7- CD45RO+ T cells 
migrate to peripheral inflamed tissue, display immediate effector function, produce 
a high amount of IFN-Y and IL-4 upon antigenic stimulation and thus are called 
effector memory T cell (TEM).69,70,71 In contrast the CCR7+ memory cells are 
central memory T cell (CEM) and express lymph node homing receptors, are 
devoid of immediate effector function, and can differentiate into CCR7- effector 
cells on secondary stimulation.  
1.8. Recirculation of memory T cells 
Distinct repertoires of adhesion receptors are expressed by the TEM and CEM 
endowing them with distinct migratory pattern and thus provide differential immune 
surveillance. TCM retain the lymph node homing receptors CD62L and the CCR7 
and thus are able to home effectively to the secondary lymphoid tissue which 
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greatly accentuate the chance of re-encountering their cognate antigen.  In 
addition, they can also localize to peripheral tissue and sites of inflammation.  
Conversely, the TEM lack the CCR7 and thus are unable to home in to the 
secondary lymphoid tissue.  In addition the memory T cell expresses a variety of 
other homing receptor conferring them tropism for specific tissue. For instance 
memory T cells homing to the skin express cutaneous lymphocyte antigen (CLA), 
72 chemokine receptor CCR473 and CCR10.74 Similarly, the memory T cell 
migrate to the small intestine expresses LPAM-1 (α4β7)75 and CCR9 which ligate 
to the Madcam-1 and CCL25 (TECK) on endothelial cells of gut lamina propria 
venules respectively.76,77  
                                   
 
  Figure 1.3: T-cell memory subtypes 
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1.9. The role of immune cells in atherosclerosis 
T cells as an important component of atheroma were first demonstrated in 1986.78 
Subsequently it was shown that T cells comprises 10–20% of the cellular 
population in early atherosclerotic lesions79,80 and in the absence of T cells, 
atherosclerotic plaque achieves only 10% of its potential size.81 Most of the T cells 
in the atherosclerotic lesion are CD3+ CD4+ cells with αβ T cell receptor.82 Due to 
ambient cytokine milieu in the atherosclerotic lesion, the CD4+ T cells are 
polarised to the pro-atherogenic Th1 lineage.83  Currently, there is a large body of 
evidence to incriminate the role of the Th1 response in all stages of 
atherosclerosis. 
However the activation of the immune system including the T cell adaptive 
response is not confined to coronary lesions. A transient burst of T-cell activation 
can be detected systemically in patients with acute coronary syndromes.84,85 
Further evidence suggests that the T cell response is antigen driven86 and is 
polarised to Th1 lineage.87  The following discussion focuses on the role of T cells 
and their pertinent phenotypical subtypes in acute coronary syndromes. 
1.9.1. CD4+CD28 null T Cells   
CD 28 is homodimer costimulatory receptor expressed on T lymphocytes. This 
molecule interacts mono-valently with two ligands, CD 80 (B7-1) and CD86 (B7-2) 
expressed on APC88 via a conserved amino acid motif MYPPY found on its 
extracellular domain. In concert with TCR signalling, CD28 enhance T cell 
activation, cell metabolism, proliferation, and survival.89,90,91 In addition, CD28:B7 
interactions are needed for development and maintenance of CD4 +CD25+ Treg.92 
 
 
24
 Although constitutively expressed, the CD 28 molecules can be down regulated 
with chronic antigenic stimulation93 as well as replicative and chronological 
senescence,94 Functionally the CD4+ CD28null cell are distinct from the classical 
CD4+ helper T cells.95 They variably express the Killer Immunoglobulin-Like 
Receptor (KIR), secrete interferon gamma, can release perforin and granzyme B. 
96,97 The KIRs belong to the multigenic family encoded within the leukocyte 
receptor complex (LCR) on chromosome 19q13.498,99 and are normally expressed 
on NK cells and infrequently on CD8+ T cells.100 The KIRs recognize MHC class I 
molecules and circumvent the need for TCR stimulation. Ligation to inhibitory KIRs 
phosphorylates the cytoplasmic immunoreceptor tyrosine-based   inhibitory motifs 
(ITIMs) which then deactivate substrates critical for cellular activation by 
dephosphorylation.  Conversely, stimulatory KIRs interact with signal transduction 
chain, DAP12101, which then activates the protein kinase cascade ultimately 
leading to degranulation of the cytotoxic granules and release of cytokines. There 
is evidence that in acute coronary syndrome there is de novo gene expression in 
the LCR locus leading to cumulative acquisition of KIR2DS2 and its signalling 
protein DAP12 endowing the CD4+CD28null cells with cytolytic competence 
circumventing the need for TCR signalling to initiate endothelial cell lysis.102  
The lines of evidence for the central involvement of CD4+CD28null cells include: 
1. The circulating CD4+CD28null cell population is amplified in acute coronary 
syndromes, constitutes up to 30-50% of total CD4+ T cell population,103 and their 
frequency predicts the risk of recurrence of acute coronary events.104 This 
expansion is probably related to the degree of systemic inflammation as their 
frequency correlated with the level of CRP105 and anti-inflammatory treatment with 
statin may reduce their frequency106  
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2. Phenotypic and TCR sequence analysis of total RNA in atherosclerotic plaques 
obtained from patients with fatal myocardial infarction indicated that these 
oligoclonally expanded population of CD28null CD4+ T cells accumulate in culprit 
lesions and are not present in non-culprit lesions107 implying they may modulate 
the stability of the plaque. 
1.9.2. CD40L+ T Cells 
CD40L (also known as CD154 and gp39) is a 39-kD protein of the tumour 
necrosis factor (TNF) family. It exists both in soluble (sCD40L) and 
transmembrane form. The transmembrane form is expressed  on cells of the 
immune system (activated CD4+ T cells, mast cells, basophils, eosinophils and 
natural killer cells108 and on activated platelets109). Expression of CD40L, 
regulated primarily by signalling through the T cell receptor, can be detected on T 
cells very early (1-2 h) after activation, peaking 6 h after activation and declining 
over the following 16-24h.110  Its target CD40,  is a 50-kDa homotrimer  of the TNF 
receptor family, constitutively expressed on professional APC and non 
professional APC like endothelial cells, vascular smooth muscle cells fibroblast 
platelets and several epithelial cells.111 
On ligation of CD40L, CD40 recruits adapter molecules TRAFs (TNF Receptor-
associated factors) to initiate downstream mediators and effectors.  Depending on 
cell type and TRAF involved the effector function can be diverse. For instance in B 
lymphocytes, CD40L-CD40-TRAF6 interaction results in isotype switching and IL-
6 production while TRAF2/3/5 binding leads to up regulation of B7.1/ B7.2 
(CD80/CD86) co-stimulatory molecule.112  In monocyte and macrophages CD40-
TRAF6 interaction leads to activation of Src/ERK1/2 and IKK/NF-kB 
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proinflammatory pathways.113  The CD40L- CD40 dyad interaction culminates in 
the expression of chemokines (monocyte chemoattractant protein-1 (MCP-1), 
interleukin-6 (IL-6) and IL-8), pro-inflammatory adhesion molecules (vascular 
cellular adhesion molecule-1, intracellular adhesion molecule-1 and P-selectin), 
and tissue factor (TF), and down regulates the expression of thrombomodulin in 
vascular cells114,115,116 -all probable participants in atherogenesis and lesion 
complication.117 Recent evidence suggests that CD40L mediates the 
proinflammatory response independent of CD40 via the integrin receptor MAC-1 
(CD11b/CD18). 118 Key lines of evidence for this are: 
1. Genetic deficiency of CD40 L leads to X-linked hyper IgM syndrome119  whilst, 
therapeutic inhibition of CD40L by monoclonal antibody resulted in immune-
suppression and increased thromboembolic phenomenon.120 The thromboembolic 
tendency is attributable to clot stabilizing effect of CD40L by alpha IIb B3 integrin-
dependent mechanism.121   Hence, inhibition of these interactions by anti-CD40L 
may render platelet plugs unstable and thus ready to embolise. Alternatively, 
interaction of the antibody with the platelet Fc receptors may promote platelet 
aggregation and thrombosis. Ligation of CD40 by CD40L is known to promote the 
expression of TF122 and procoagulant leukocyte-derived microparticles expressing 
TF are a potent source of fibrin deposition on activated platelets.123,124 Although 
lack of CD40L may be associated with thrombus fragility, high levels of soluble 
CD40L, which have been reported in patients with unstable angina,125 could 
constitute an increased risk factor for thrombosis especially in regions of stenosis 
(high shear rate).  
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2. Epidemiologically, soluble CD40L (sCD40L), the 18-kDa extra-cellular portion of 
the trans-membrane molecule, is considered a predictor of cardiovascular risk.126, 
127,128 
3. Experimental evidence from LDLR-/- and ApoE-/- mice that genetically lacked 
CD40L or those treated with neutralising anti-CD40l antibodies suggest that 
CD40L inhibition attenuates atherogenesis, and modifies the plaque in to a 
phenotypically more stable composition,129,130 and abrogates progression of pre-
existing atherosclerotic lesion.131,132 
4. T cells expressing CD40L have been observed within atherosclerotic plaque in 
human subjects.133 Since the CD40L regulates the expression of interstitial 
collagenase (MMP1), activated gelatinase (MMP-2), stromelysin (MMP-3) and 
gelatinase B (MMP-9) in human vascular smooth muscle cells (SMCs)134 the 
CD40L-CD40 dyad may promote plaque instability. T cells in peripheral blood of 
patients with unstable angina had enhanced surface expression of CD40L and 
increased release of sCD40L on anti-CD3/anti-CD28 stimulation in vitro when 
compared with patient with stable angina and controls.135 
1.9.3. HLA-DR+ T cells 
 1. HLA-DR+/IL-2R+ T lymphocytes are present in fatty streaks and fully developed 
atherosclerotic plaques.136,137,138 Moreover, HLA-DR+ T cells are almost a 
constant finding at rupture sites of thrombosed coronary plaque of patients who 
have died of acute myocardial infarction.139  
2. The frequency of HLA-DR+ T lymphocytes in atherosclerotic lesions is 
increased as compared to peripheral blood lymphocytes, and the same is true for 
the activation markers VLA-1, CD26, CD38, and CD45RO.140  
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1.9.4. OX40+ T Cell 
Ox40 (CD134) are type I transmembrane protein of the TNFR family,141 which 
forms trimeric signalling complexes when interacting with its cognate ligand 
OX40L (GP34). The expression of OX40 on T cell and OX40L on APC is 
inducible, occurring several days after antigen recognition by the TCR and 
peaking 2-4 days in to the response.142,143 The level of expression and its kinetics 
is augmented by the costimulatory CD 28-CD80/CD86 interaction.144  This dyad is 
involved in the generation of memory T cells,145 enhancing cell survival by up 
regulating the antiapoptotic proteins BCL-XL and BCL2,146 cytokine production147 
and T cell migration and tissue infiltration through interaction with OX40L on 
endothelial cells. 148,149 OX40 - OX40L is expressed in a number of autoimmune 
conditions.150,151,152,153,154  Lines of evidence supporting involvement in atheroma 
and myocardial infarction include: 
1. Genetic studies have identified OX40L gene underlying the atherosclerosis 
susceptibility locus Ath1 on chromosome 1, and genetic variations in the OX40L 
locus are associated with myocardial infarction and severity of CAD in man.155  
2. The quantitative trait locus for MI in human is located on chromosome 4, in the 
same region as OX40,156  and genetic polymorphism of the OX40 gene may 
influence susceptibility to MI.157  
3. Mice over expressing OX40L showed significantly larger atherosclerotic lesions 
compared with control, and mice with targeted deletion of this gene (Tnfsf4-/-) 
results in significantly smaller lesions compared with control.155  
4. Inhibition of OX40L in a LDLR-/- mice with anti-OX40L antibody, significantly 
attenuates the volume of atherosclerosis and cellularity of the plaque.158 
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1.9.5. Antigens for the T cell Response 
Chronic phase 
The evidence that antigen presentation plays a role in atherogenesis is derived 
from that fact that professional antigen presenting cells like CD1a+ dendritic cells 
have been reported in vascular intima.159,160 As the initial cell type observed 
infiltrating the arterial intima at a site known to be predisposed to later 
development of atherosclerotic lesions were lymphoid cells, and not foam cells,161 
and the CD4+ lymphoid cells were HLA-DR and CD25 positive, the expression of 
the MHC molecules is indicative that antigen presentation has occurred and an 
immunological reaction is ongoing or has recently happened.162    
Acute Phase 
Progression of atherosclerosis to unstable rupture prone plaque may also be 
antigen driven as mature DC has been reported amongst the clusters of activated 
T cells in rupture prone areas of atherosclerotic plaque. 163,164   
 The putative antigen recognised by the T cells includes exogenous microbial 
components or autologous proteins for instance, B-2 GP-1, oxidised LDL (oxLDL), 
and stress or heat shock proteins (HSP).  
1.9.5.1. Heat Shock Protein 
HSP are evolutionarily conserved proteins of various molecular weights expressed 
both in eukaryotes and prokaryotes. They function as molecular chaperones and 
are responsible for a wide range of physiological function including translocation of 
oligomeric protein,165 assembly and folding of nascent protein, cellular signalling, 
and protein degradation, resolubilize aggregated protein.166,167 They are 
expressed constitutively but are inducible in response to various noxious stimuli 
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for instance, hemodynamic stress,168 oxidative stress,169 LDL and oxLDL,170 via 
the mitogen activated protein kinase (MAPK) pathway. 
HSP 60 is a mitochondrial protein that is translocated in to the cytoplasm in 
response to stress and have potential to be transported to the cell surface where it 
seems to provide a danger signal.171,172 The HSP60 family comprises the human 
HSP60, hHSP60; mycobacterium homologue, mHSP65; Chlamydia homologue, 
cHSP60; and E Coli homologue GroEL,173 the last three exhibiting more than 90% 
sequence homology amongst themselves and 50%-55% with hHSP60.174  This 
degree of phylogenetic conservation confers the opportunity by which immune 
response directed to microbial HSP60 can be redirected against hHSP60 when it 
is induced in situ in response to stress and initiate autoimmune damage by 
process of molecular mimicry.   
In experimental studies, immunisation of normocholestrolemic rabbits with 
Freund`s complete adjuvant ( which contains mHSP65) or recombinant mHSP65 
resulted in mononuclear cell infiltration of the intima at those arterial site that are 
known to be subjected to major turbulent hemodynamic stress175 and peripheral 
blood showed antibodies and T cells reactive to HSP.176 Similarly, Wild-type mice 
(C57BLy6J), which are very resistant to induction of atherosclerosis by a high 
cholesterol diet alone, also develop aggravated lesions when simultaneously 
immunized with mHSP65.177 Immunization of the LDLR-/- mice with HSP65 
induced specific T cell reactivity against mHSP65 as well as mammalian HSP60. 
Transfer of lymphocytes or isolated IgG of immunized mice into non-immunized 
litter-mates enhanced lesion size.178 
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In addition to expression of HSP60 in the cellular components of atheroma,179,180 
T cells reactive to HSP60 have been localised in human atherosclerotic 
lesions.181,182 Further, peripheral T cell reactivity against HSP60 has been shown 
as an independent predictor of early intima media thickening in young subjects183 
although no such association was found in older subjects.184 With advanced 
atherosclerosis, CD4+CD28null cells in the peripheral circulation were found to be 
reactive to hHSP60 during the acute phase of coronary artery disease and not 
during the chronic stable phase.185  
Epidemiological studies have incriminated anti-HSP65 antibodies to be associated 
with risk of atherosclerosis;186 their titre correlated with disease severity187,188 and 
was shown to predict 5-year mortality.189 AntimHSP65 antibody titre correlated 
strongly with human IgA to C. pneumoniae and IgG to H. pylori implying a role for 
these infections in the production of mHSP antibodies.190 A subsequent study 
related elevated human HSP60 IgA antibody levels in conjunction with elevated C. 
pneumoniae IgA antibody levels and an elevated CRP with a relative risk of 7.0 for 
coronary events.191 Experimental studies suggest that in the presence of 
complement (complement-mediated cytotoxicity) or peripheral blood mononuclear 
cells (antibody-dependent cellular cytotoxicity), these antibodies can lyse stressed 
endothelial cells.192,193   
1.9.5.2. OxLDL 
 
Oxidised LDL (oxLDL) is present in atherosclerotic lesions and comprises a 
variety of lipid peroxidation products. They can ligate to various macrophage 
receptors including CD36, SR-B1194,195 and CD14/TLR4196 to elicit innate immune 
response; or behave as immunogenic neoepitopes to elicit adaptive immune 
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response. 197 T cells isolated from human atherosclerotic plaque were shown to be 
specifically reactive to oxLDL in MHC class II restricted fashion, 198 and plasma 
titres of antibodies against oxLDL may accentuate atherosclerosclerosis.199 
1.9.5.3. ß2 Glycoprotein-I (ß2 GPI) 
 
ß2 GPI is a phospholipid binding protein expressed by platelets, endothelial cells 
and human atherosclerotic plaque.200 Adoptive transfer and immunisation of 
LDLR-/- mice against ß2 GPI accelerated early atherosclerosis.201,202 This effect 
may be due to the effect of the antibodies on macrophage leading to enhanced 
uptake of the oxidised LDL by macrophages.203    
1.9.5.4. Infections 
 
Seroepidemilogical studies have associated the risk of atherosclerotic 
cardiovascular disease with serum antibody titres against various microbial 
pathogens including C. pneumoniae,204 H. pylori,205 CMV,206 EBV,207 periodontal 
pathogen208 and entero virus.209 However, the serological association is rather 
disparate.210,211 Subsequent studies indicated an association of CHD with serum 
IgA and not IgG.212 Further, co-infection with multiple pathogens and the 
cumulative pathogen burden seemed to have synergistic effect in induction of 
vessel injury.213,214   
C. pneumoniae has been detected in human plaque.215,216, 217  T cell lines specific 
to Chlamydia pneumoniae have been generated from atherosclerotic plaque218  
and they specifically react to cHSP60 and membrane antigen from C 
pneumoniae.219 Similarly multiple members of herpes virus family220 and DNA of 
several pathogens responsible for periodontal pathology has been isolated from 
human atherosclerotic plaque221 and plaque-derived T cells reactive to respective 
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pathogens have been identified.222,223 As eluded to earlier, these HSP reactive T 
cells in turn evoke autoimmune response due to antigenic cross reactivity leading 
to plaque inflammation.  
Acute respiratory infection during the two preceding weeks has been shown to be 
a risk factor for acute myocardial infarction.224 Further, in patient with ACS serum 
levels of antihuman HSP60 IgG antibody and anti-chlamydial IgM but not IgG or 
IgA were significantly higher when compared with stable CAD and controls.225 
This implicates the role of acute infection in destabilization of atheromatous 
plaque.     
1.9.6. Antigen independent T cell activation 
Independent of direct antigen presentation, interleukin-15 exerts pleotropic effects 
on T cell functions including proliferation, differentiation, cytokine production, 
apoptosis inhibition and induction of CD40L and CD69 expression.226,227,228 
Plaque macrophages express high level of IL-15 mRNA and its protein especially 
in lipid rich plaque.229 Since high lipid content renders plaque vulnerable for 
rupture, one may speculate this mechanism may be responsible of acute 
instability of plaque.   
1.9.7. Role of cytokines  
1.9.7.1. Interferon-γ 
Interferon gamma is the principle proatherogenic cytokine expressed by the T 
cells in atherosclerotic plaque.230 In ApoE-/- mice, deficiency of interferon-gamma 
or its receptor attenuates atherosclerosis,231,232 and conversely, injection of 
recombinant interferon-gamma accentuates atherosclerosis.233  
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T lymphocytes accumulate at sites where plaques rupture and cause fatal 
thrombosis;234 such plaques typically have relative paucity of vascular SMCs and 
interstitial collagen matrix rendering them vulnerable for rupture. Compared to 
regions lacking T-cell infiltrates, sites where T-cell accumulates exhibit low levels 
of interstitial collagen mRNA and protein.235 Interferon- gamma inhibits interstitial 
gene expression and protein synthesis in these cells.236 In addition, apoptosis 
may contribute to the paucity of SMCs in vulnerable plaques.237 Indeed, some 
SMCs in atheroma have fragmented DNA and other features characteristic of 
programmed cell death.238 Pro-inflammatory cytokines like interferon-gamma 
expressed in atherosclerotic plaques can trigger apoptosis.239 SMCs in the 
atherosclerotic intima can express fas, while T cells in the atheromata express fas 
ligand-bearing.240,241 Thus, the T cells in concert with the inflammatory cytokines 
like interferon gamma destabilize the plaque leading to acute coronary 
ative that interferon-
rosclerotic lesions than mice that received bone marrow from IFN-γ 
+/+mice.245 
syndromes. 
 Clinical studies have revealed interferon-gamma producing CD4 and CD8 T cells 
are increased in peripheral circulation in patients with an acute coronary 
syndrome.242 Although the plasma level of interferon-gamma may not be grossly 
elevated,243 the up-regulation of interferon-gamma–inducible genes for 
transcription of IP-10 and CD64 in circulating T cells is indic
gamma activity is augmented in acute coronary syndrome.244 
Surprisingly LDLR-/- mice transplanted bone marrow from IFN-γ-/- mice exhibited 
larger athe
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1.9.7.2. Interleukin 12 
Interleukin-12 is the principal cytokine to promote Th1 differentiation and 
atherogenesis by inducing IFN-γ production from Th1 cells. Administration of 
recombinant IL-12 to ApoE-/- mice could accelerate atherosclerosis with 
concomitant augmentation of interferon-gamma expression.246 Conversely, apoE-
/-IL12p40-/- mice exhibited reduced plaque burden.247  In humans, IL-12 mRNAs 
and protein were significantly expressed at atherosclerotic plaques.248  This 
cytokine may be important in progression of atherosclerosis to acute coronary 
syndrome as elevated plasma level of IL-12 has been detected in unstable 
angina249 and acute myocardial infarction.250 
1.9.7.3. Interleukin 18 
 
IL-18 is pleiotropic cytokine acting in both acquired and innate immunity.251 It acts 
synergistically with IL-12 for activation of Th1 and production of IFN-γ.252 ApoE-/-
IL18-/- mice253 and ApoE-/- mice treated with plasmid DNA encoding for IL-18 
binding protein254 exhibited attenuated atherosclerosis, whilst, IL-18 administration 
enhanced atherosclerosis in ApoE-/- mice.255 However, IL-18 administration did 
not alter atherosclerosis in ApoE-/-IFN-γ -/-mice implying IL-18 modulates the 
atherogenic effect by induction of interferon gamma.   Increased expression has 
been reported in human atherosclerotic plaque256 and increased plasma 
concentration in AMI.257 Plasma IL-18 up regulates Fas ligand258 and 
concentrations are increased in patients with acute coronary syndromes and 
correlate with the severity of myocardial dysfunction.259  
 
 
36
1.9.8. Atheroprotection: Foxp3  Tregs: CD25+ CD4+ T Cells 
Tregs are subset of CD25+ CD4+ T cells   and express lineage specific marker 
FOXP3 (Forkhead Box Protein P3), a member of the forkhead winged helix 
protein family of transcription factors.260,261 Natural Treg arise in the thymus while 
Adaptive Foxp3+ T cells can develop from naïve CD25- Foxp3- CD4+ T cells in 
response to antigen and driven by TGF-B.262,263  High levels of CTLA-4 (cytotoxic 
T-lymphocyte associated molecule-4), CD103 and GITR (Glucocorticoid-induced 
TNF receptor) are also expressed on Treg. However, the functional significance of 
this expression remains to be elucidated. Tregs constitute 10% of peripheral CD4+ 
T cells264 and are implicated in inducing and maintaining immune tolerance and 
the termination of immune responses. Their suppressive effect appears to be 
contact dependent and probably mediated by TGF-B.265 Their deficiency leads to 
inflammatory autoimmune disorder266 and attenuated peripheral blood 
CD4+CD25high Treg have been linked to different types of autoimmune diseases like 
rheumatoid arthritis, type-1 diabetes, multiple sclerosis and systemic lupus 
erythematosus.267,268  
Experimental studies have suggested adoptive transfer of Treg prevented 
development of plaque in mouse ApoE-/- model of atherosclerosis.269,270 The 
natural Tregs are known to produce IL-10271 which may have a critical role in Treg 
mediated suppression,272,273 and IL-10 are associated with attenuation of 
experimental atherogenesis.274,275,276 The suppressive effect of Tregs may also be 
mediated by transforming growth factor-beta as its mRNA can be predominantly 
detected in the CD25+ CD4+ population.277 Neutralising anti-TGF-β antibody278 
and soluble TGF-β receptor279 accelerated atherosclerosis in ApoE-/- mice, and 
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delivery of activated TGF-β to LDLR-/- mice via adenovirus vector attenuated 
atherosclerosis.280  
In Man, Tregs has been demonstrated in peripheral blood of subjects with normal 
coronary arteries281 and is decreased in the peripheral blood of patients with acute 
coronary syndromes.282,283 Further, the frequency of FOXP3+ Treg in 
atherosclerotic lesion was found to be attenuated and quantified to be in the range 
of the 0.5–5% of the total number of CD3 + T cells.284  
CD 25 is the alpha subunit of the IL-2 trimeric molecule. CD25+ T cells are 
expressed constitutively in 5-10% of peripheral CD4+ T cells.285  CD25 expression 
may not be the specific phenotypic marker of FOXP3+ Treg as CD25 is induced on 
T cells within 2-24 hours after stimulation by cytokines and persists for few days 
after diminution of the stimuli.286,287 Unlike FOXP3+ Tregs, the CD25+ T cells were 
more prevalent in atherectomy specimens from patients with refractory unstable 
angina and acute myocardial infarction compared with specimens from patients 
with stable angina.288,289  
1.10.  Hypothesis for this thesis 
The hypothesis for this thesis is that a study of thromboaspirate obtained at PPCI 
for STEMI in man may allow further elucidation of the immunological mechanisms 
involved in the processes of atherogeneis, plaque rupture, thrombotic coronary 
occlusion and microvasular and myocyte damage associated with reperfusion in 
STEMI.  
1.11.  Outline plan of investigation 
This exploratory investigation will use thromboaspirate obtained at PPCI for 
STEMI in man. The material obtained will be filtered so that that both solid phase 
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thrombus and liquid phase filtrate can be analysed. Specifically the solid thrombus 
will be examined for platelet and leukocyte composition and the liquid phase will 
be analysed focussing on T cell phenotypes and immunoregulation. In addition the 
cytotoxicity of coronary sera will be explored in a set of preliminary investigations. 
For liquid phase assays comparison will be made with chronic stable angina 
patients and healthy volunteers. 
1.12 General statistical and sample size considerations 
The work of this thesis explores novel approaches in the investigation of 
intracoronary biology in patients. Limitations imposed by the nature of the work 
are discussed in the methods section and individual chapters. Statistical issues 
have been reviewed in detail with our statistician (MR) and conclusions are limited 
to the exploratory mechanistic nature of this work. The presentation of results and 
statistical comparisons is discussed in detail in the methods chapter (2).  
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 CHAPTER 2: Methods and Materials 
2.1. Recruitment of test cohort 
 
I personally attended two hundred primary percutaneous interventions (PPCI) for 
patients with ST elevation myocardial infarction (STEMI) from November 2006 to 
May 2008 at Harefield Hospital and recruited 75 subjects. Since the patients at 
arrival to the hospital are sometimes under the influence of narcotic analgesia 
impairing their competence for giving informed consent, and the process of 
prospective consenting could interfere with the clinical care delaying myocardial 
reperfusion, it was agreed by the ethics committee that retrospective consent be 
sought for research using samples aspirated for clinical indications.  
2.1.1. Inclusion criteria: 
 
• Chest pain of 12 hours duration or less 
• ST elevation of at least 2 mm in two consecutive precordial  leads or at least 
1 mm ST elevation in two consecutive limb leads or new onset LBBB with chest 
pain 
• Consented for PPCI 
• Angiographic evidence of thrombotic occlusion of the coronary artery (TIMI-0 
flow) 
• Thromboaspiration performed on clinical grounds with the sample aspirated 
available for analysis 
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2.1.2. Exclusion criteria: 
• Refusal or unable to consent 
• Acute / subacute stent thrombosis 
• Spontaneous TIMI II –TIMI III flow  
• Transplant recipients 
• Active autoimmune disease 
• Known blood dyscriasias 
• Immunosuppressive therapy 
• Heart Failure 
2.2. Recruitment of control cohort  
Twenty age and sex matched patients attending Harefield Hospital for the 
investigation of known coronary artery disease with coronary angiography.  
2.2.1. Inclusion criteria 
• Known chronic stable angina undergoing coronary angioplasty 
• Undiagnosed chest pain undergoing coronary angiography 
• Patients undergoing angioplasty restudy / CABG restudy 
2.2.2. Exclusion criteria: 
• Troponin positive ACS (preceding 3 months)  
• Transplant recipient 
• Autoimmune disorder 
• Heart Failure 
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2.3. Clinical Characteristics 
 
 STEMI 
(n=75) 
CSA  
(n=20) 
Healthy  Volunteer 
(n=10) 
Age: Mean years.  61 (19) 54 (12) 30 (4) 
Sex (% Male) 66.6 80 50 
Pain to reperfusion time: Minutes(SD) 186(168) N/A N/A 
Peak Creatinine Kinase U/l(SD)  1315 (1117) N/A N/A 
Peak Troponin I ug/l (SD) 94 (198) N/A N/A 
Total Cholesterol mmol/l (SD) 5.9 (1.3) 4.5 (1.4) N/A 
Random Glucose mmol/l (SD) 9.7(6) 7 (2) N/A 
Hypertension %  53.3 60 0 
Hypercholesterolemia  % 29.4 40 0 
Diabetes %       26.7 30 0 
Current Smoking % 33 25 0 
Family history of premature CAD  % 24 25 0 
Prior Beta Blocker use % 24 70 0 
Prior ACE inhibitor use % 25 65 0 
Prior Statin Use % 37.8 90 0 
Prior Clopidogrel use % 6.7 25 0 
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 2.4. Plan of investigations 
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Figure 2.1: Plan of investigation 
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 2.5. Sample collection 
2.5.1. Intracoronary thrombectomy and aspiration 
The intracoronary aspiration was performed using a sterile non-pyrogenic 
aspiration catheter (Export® XT Aspiration catheter, Medtronic, Minneapolis, USA) 
(figure 2.1-3). The catheter was 140 cm long and has a dual lumen radio-opaque 
tip with total diameter of 1.73mm. The catheter was advanced over the guide wire 
under fluoroscopy. Once the tip was advanced to the point just proximal to the site 
of coronary occlusion a negative pressure was applied using a 20ml syringe and 
the catheter was advanced forward and backward to obtain the atherothrombotic 
material. Haemodynamic data provided by the manufacturer (Medtronics, 
Minneapolis, USA) suggest that the catheter evacuates fluids and debris at a 
minimum flow rate of 0.5ml/sec.  Using the Hagen-Poiseuille formula assuming 
steady flow, a rigid tube and a parabolic velocity profile, shear rate for the system 
was (4Q/πR3) 0.05 S-1.  This shear rate is small when compared for example with 
the rate produced within the vacutainer (Becton Dickenson) system commonly 
used for venepuncture.  Assuming similar flow conditions, 4.5ml aspiration would 
take almost 10 sec giving a flow rate of 0.45ml/sec. Since the internal diameter of 
21 gauge needles was 0.5mm, the average shear rate was 4500S-1.  Since the 
shear rate in the aspiration devise was comparatively low we did not anticipate 
major activation of platelets induced artefactually by the shear rates.  
The aspirate was then filtered through a filter with pore size 0.79 mm to separate 
the athero-thrombotic material from blood (Figure).  The ex-vivo coronary thrombi 
were embedded in Optimal Cutting Temperature (OCT) compound (Tissue-Tek; 
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Miles Laboratories Inc., Elkhat, IN), cryofrozen and stored at -80 °C. The coronary 
filtrate was divided into three aliquots for:  
• Whole blood preparation for Leukocyte experiments.  
• Centrifuged at 200g for 10 minutes to obtain platelet rich plasma (PRP) for 
platelets experiments. 
• Centrifuged at 3000 rpm for 10 minutes to obtain Platelet poor plasma (PPP). 
The supernatant PPP was pipetted off and stored at -80 °C.   
 
 
 
 
 
 
 
 
Export® XT Aspiration catheter, Medtronic, Minneapolis, USA 
    Figure 2.2: Thrombus aspiration catheter 
 
 
 
 
  
 
 
 
Figure 2.3: Ex vivo intra-coronary thrombus from patient with STEMI 
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2.5.2. Femoral arterial blood sampling 
 
Femoral arterial blood sampling was obtained through the side port of the femoral 
introducer (Avanti® cordis, Miami, FL, USA) using a 20 ml syringe. The introducer 
was 11 cm long with 5F-6F (1.65 - 2mm) lumen diameter. The sampling was 
performed prior to delivery of any anticoagulants or glycoprotein IIb/IIIa inhibitors. 
The blood was then transferred to EDTA vacutainers without using any needle to 
minimise the shear rates. The femoral blood was also divided in three aliquots as 
explained above for paired experiments.   
2.6. Sample processing 
2.6.1. Whole blood preparation for flow cytometry  
 
2 μL of the whole blood in a 1.5 ml eppendorf tube was diluted 10X with modified 
Tyrode's solution (composition in mM: NaCI 140, KCI 5.4, CaCI2 1.8, MgCI2 0.5, 
HEPES 5, D-glucose 5). At this dilution, the approximate number of cells present 
in each eppendorf tubes provided that the total blood counts in the blood were 
within normal range would be: WBC: 20,000, with lymphocytes: 8,000, neutrophils: 
10,000 and monocytes: 1,600; total platelets: 300,000; and RBC: 10X106. (figure 
2.4). The cells were stained with a saturating dose of monoclonal antibodies and 
incubated at room temperature for 30 minutes. 400 μL of 1X BD FACSTM lysing 
solution (BD Bioscience, San Jose, USA) was then added and incubated for 30 
minutes in the dark at room temperature to lyse the red cells. To label leukocytes, 
Hoechst 33342 (Molecular Probes, Eugene, OR, USA), diluted in PBS (1 µg/L final 
concentration), was subsequently added for another 30 min.290 
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                                  Full blood count in whole blood                          Full blood count in 10X diluted blood 
Figure 2.4: Whole blood preparation for flow cytometry 
 
2.6.2. Buffy coat preparation for flow cytometry  
Five ml of the blood sample was centrifuged at 200Xg for 10 minutes. The cells at 
the interface were pippeted off. Contaminating red cells were removed by cell lysis 
by osmosis. The protocol used at our centre included addition of 9 ml of distilled 
water in to the preparation and gentle mixing by inversion for 20 seconds. Adding 
1 ml of 10X PBS then reversed the osmosis. The cells were pelleted by 
centrifugation at 1500 rpm for 6 minutes. The supernatant was discarded and the 
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pellet washed twice with Hanks (Sigma). Finally the cells were suspended in 
RPMI-1640 (Sigma). 
2.6.3. Mononuclear cells by density gradient centrifugation for flow 
cytometry  
 
Five ml of the whole blood was diluted with iso-volume of phosphate-buffered 
saline (PBS). The mixture was layered over 15 ml of Histopaque-1077 (Sigma, St. 
Louise, Missouri, USA). Mononuclear cells were collected from the interface after 
density centrifugation at 1500 rpm for 20 minutes. The cells were washed three 
times with Hanks (Sigma) after centrifuging at 1500 rpm for 5 minutes. The pellet 
was suspended in 1 ml RPMI-1640 (sigma). A haemocytometer was used to 
calculate the number of cells per ml. The cell suspension was appropriately diluted 
to obtain 1 million cells per ml.  
2.6.4. Cryo-sectioning of the thrombus 
 
The ex-vivo frozen thrombi were subjected to serial cryotomy at -19°C to -22°C to 
obtain 5-micron sections. The sections were mounted on glass slides, incubated 
at 37°C for 30 minutes, and fixed with acetone for 5 minutes. The slides were 
wrapped with cling film and stored at -80°C.  
2.6.5. Immunohistochemistry 
 
Cryostat sections were fixed with acetone for 5 minutes and incubated with 5% 
normal goat serum and 1% bovine serum albumin (BSA) for 30 minutes to block 
the non-specific binding sites. A panel of primary antibody suspended in 1% BSA 
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was add in to the spots and incubated at room temperature for 1 hour. The 
sections were washed thrice in PBS for 5 minutes, incubated with secondary 
antibody for one hour and again washed thrice in PBS.  
The sections were visualized using a three-color immuno-microscope (Nikon, 
Japan). Individual cells were quantified by measuring the intensity the specific 
fluorphore using Lucia-G software (Laboratory Imaging Ltd., Prague, Czech 
Republic). Ten random high power fields were analysed in each section numbers 
of positive cells/high power fields. 
 
2.7. Flow Cytometry 
2.7.1. Principles 
 
Flow cytometry was used to analyze the optical properties (light scattering and 
flurochrome emission) of 0.2-150 μ particles or cells in mono-disperse suspension, 
hydro-dynamically focused in to single file and subjected to the laser intercept to 
generate specific multi-parametric data pertaining to its physical and chemical 
composition. Forward-scattered light (FSC) is an index of mostly diffracted light 
and is detected just off the axis of the incident laser beam in the forward direction 
by a photodiode and correlates with cell volume. Orthogonal or side-scattered light 
(SSC) is a measurement of refracted and reflected light that occurs at any 
interface within the cell where there is a change in refractive index.   SSC is 
collected perpendicular to the laser beam and is proportional to cell granularity or 
internal complexity. Two parameter histogram-correlating measurements of FSC 
and SSC can allow for differentiation of cell types in a heterogeneous cell 
population (figure 2.5).  
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Figure 2.5: Whole blood FACS after red cell lysis using FSC and SSC 
2.7.2. Optics 
When excited with a laser beam of a particular wavelength, a fluorochrome 
specific for that wavelength absorbs light and elevates electrons to a higher level 
of energy.  The excited electron quickly decays to its ground state, emitting excess 
energy as photon of light of specific wave length. Monoclonal antibodies against 
both extra-cellular and intra-cellular antigens can be conjugated with different 
flurochromes and particular cell type can be identified.  Combinations of 
fluorophores with varying emission spectra can be used for detailed phenotyping 
of a particular cell of interest or in heterogenous cell populations to distinguish 
separate subpopulations.  The following illustration depicts the absorption and 
emission spectra of various flurochromes used in our experiments (figure 2.6).  
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Figure 2.6: Absorption and emission fluorochrome spectra 
The emitted fluorescence and SSC signals are diverted to the photomultiplier 
tubes (PMTs), and a photodiode collects the FSS signals. These light signals are 
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converted to electronic signals (voltages) by photo detectors and then the voltage 
pulse is assigned a digital value by the Analog-to-Digital Converter (ADC) and is 
displayed in an appropriate position on the data plot.   
2.7.3. Methodology 
 
 In our centre flow cytometric analysis was performed on the BD fascaria equipped 
with three lasers at 488 nm (argon), 633 nm (Helium-Neon), and 405 nm (Diode). 
Analysis was performed within two hours of sample collection. The 
multiparametric resolution of the side and forward scatter was optimised for 
resolving lymphocytes, monocyte and granulocyte population. Appropriate 
electronic threshold parameters were set to eliminate debris and cell fragments. 
Non-specific staining with the isotype-matched control monoclonal antibodies was 
kept below 1%.  The intrinsic spectral overlap of the different fluorochromes while 
performing simultaneous multicolour flow cytometry could cause spurious events 
being recorded in inappropriate detectors in multi-colour contour plots leading to 
false positive population. This effect was mitigated by electronic subtraction of 
unwanted emission to remove the effects of spectral spill-over by using 
appropriate single and double stained control samples.  
2.8. Investigation of potential confounding factors 
 2.8.1. Contrast media effect  
Iodinated angiographic contrast media can influence haemostasis; and both 
prothrombotic291,292 and anticoagulant293,294 effects have been previously been 
described.  This effect is probably mediated by the effect of the contrast media on 
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the platelets which degranulate in response to the low osmolar contract media 
leading to expression of CD62P, CD63 (GP53), release of α-granules (PF4) and  
dense granules (5-HT). Since coronary blood aspiration was performed 
subsequent to intracoronary injection of contrast media in to an occluded coronary 
artery, it was possible that the difference observed on coronary aspirate when 
compared with femoral arterial sample (sampled prior to contrast) could be the 
spurious effect of the contrast media.  Therefore, to identify the effect of contrast 
media on different cell lines, femoral arterial blood from 5 controls (patients with 
stable coronary artery disease undergoing angiography) was admixed in serial 
dilutions (figure 2.7) with the contrast media in-vitro and then subjected to 
standard whole blood flow cytometry.  
For platelet experiments, as per the standard practice, the 1.5 ml Eppendorf tubes 
are centrifuged at 200g for 10 minutes to obtain platelet rich plasma. As shown in 
the figure platelet rich plasma was obtained consistently on aliquot 1 and 2. 
Aliquot 3 also separates into plasma but was contaminated with RBC. Since the 
coronary aspirate on all test samples separated into plasma without any RBC 
contamination, one can infer that the maximum concentration of the contrast in the 
coronary aspirate has to be less than 250 μL in 1.5 ml.  Furthermore when the 
coronary aspirate was obtained hardly any residual contrast was visualised inside 
the coronary artery on the fluoroscope.      
Blood+CM  Aliquot 1 Aliquot 2 Aliquot 3 Aliquot 4 Aliquot 5 Aliquot 6 Aliquot7 
Contrast Media  Nil 125μL 250μL 375μL 500μL 750μL 1000μL 
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Figure 2.7: Controlling for contrast media effect 
 
The PRP obtained from the whole blood, as well as the serial dilution at 125μL 
contrast /1.5 ml of blood and 250μL contrast /1.5 ml blood were stained with the 
same panel of antibodies as the test samples to evaluate the effect of the contrast 
media. 
2.8.2. Effects of shear rates 
As discussed earlier in section 2.5.1, the hemodynamic profile of the aspiration 
device, the Export® XT, allows a minimum flow rate of 0.5ml/sec engendering 
minimum shear rates of 0.05 S-1.  Although this shear rate is small, the total 
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duration for which the cells are exposed to this shear rates is significantly higher 
than the vacutainer as the length of the Export® XT devise is 140 cm.  To 
evaluate whether the observed difference between coronary aspirate and femoral 
blood was attributable to the shear rates in the Export® XT devise, femoral arterial 
blood obtained from 5 patients undergoing coronary angiography was aspirated in 
vitro using the Export® XT devise.  The paired femoral and the post aspiration 
samples were subjected to staining procedure similar to the test samples and 
analysed in the flow cytometer.  
 
2.8.3. Reliability 
To evaluate the repeatability (test retest) of the overall procedure (venessection, 
collection and flow cytometry) serial peripheral venous samples from 10 healthy 
volunteers were obtained at an index time and 2 hours later. The whole blood and 
PRP obtained from both samples were stained as per standard per standard 
protocol and subjected to flow cytometry.  The data was analysed to obtain the 
mean difference.   
2.9. Statistical considerations 
These experiments have been performed on relatively small numbers of patients. 
All raw data has been analysed for normality of distribution and a degree of 
skewing was seen in some of the distributions, following statistical review it was 
concluded that the data should be described using nonparametric parameters in 
terms of median and quartile range and this is the format used throughout the text. 
Unless iterated to the contrary therefore, the numerical immunological data is 
presented as median with 1st and 3rd quartiles in brackets. Statistical analysis are 
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performed using wilcoxon signed rank test while analysing one subject two sample 
measures and Mann-Whitney test while comparing two different cohorts like 
STEMI versus chronic stable angina patients.  In the figures however the graphs 
are presented as the median (solid line) interquartile range (shaded box) and 
range (whiskers) to give the reader a clear picture of the totality of the data 
including the range.  Correlations between continuous variables are assessed with 
linear regression analysis, and the corresponding r squared value and Pearson 
correlation coefficients are calculated. Statistical significance is accepted as 
conventional 2-tailed p <0.05 and is mentioned where it is significant. Where p=ns 
is used, the p-value is greater than 0.05.   Given the small sample size, 
interpretation of 40 
the p-values is conservative in this text, and the differences for which true 
significance is claimed are statistically robust and reach significance with both 
parametric and non-parametric statistical methodology. 
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 CHAPTER 3:  SOLID PHASE CORONARY THROMBUS  
 
3.1. Background 
Formation of thrombus on disrupted atherosclerotic plaques is the fundamental 
event in the development of acute coronary syndromes and in the progression of 
atherosclerosis.295 The basic component of the thrombus includes polymeric 
scaffolds of fibrin and enmeshed platelets, erythrocytes and leukocytes. However, 
as discussed in the introduction, published data on the proportional composition of 
these components is variable. There is significant morphological heterogeneity 
within a thrombus due to polarity of distribution of platelets and erythrocytes. The 
platelets cluster on the “head end” which is in continuity with the plaque crater 
while the tail end is chiefly composed of erythrocytes and fibrin as shown 
schematically in the following figure (3.1).  
 
 
 
 
 
 
 
 
RBC Tail  
 
Plaque 
 
 Platelet Head
 
Figure 3.1: Illustration of thrombus orientation 
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Much of the available data relating to coronary thrombus composition has been 
obtained from necropsy, which has its inherent limitations. A detailed 
compositional analysis of the ex vivo thrombi aspirated during STEMI however 
may provide more clinically relevant data.  
Despite administration of multiple antiplatelet and antithrombotic therapies, 
recurrence of coronary events sometimes occurs in clinical practice, which may 
indicate involvement of other cell types in acute coronary events.  Therefore in this 
chapter we aim to focus on the presence of leukocytes and subpopulations in the 
coronary thrombus.   
3.2. Method  
Five μm cryostat sections of the 15 ex-vivo coronary thrombi were subjected to 
immuno-staining as described in chapter 2 using the following panel of antibodies:  
 
 Primary antibody Secondary antibodies 
Platelets CD42a-PerCP 
CD41a-PerCP 
PAI-1-FITC 
CD41a 
Alexa Fluor- 350 
Leukocytes DAPI 
CD14- PE-Cy5 
CD11b-PE-Cy5 
CD3-FITC 
CD20-FITC 
Vimentin - Alexa Fluor-647 
Fibrin Fibrin-FITC  
The sections were visualized using three-color immuno-microscope (Nikon, 
Japan). Individual cells were quantified by measuring the intensity the specific 
fluorphore using Lucia-G software (Laboratory Imaging Ltd., Prague, Czech 
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Republic). Because of heterogenous morphology of the thrombus, area of interest 
was identified by presence of nuclear signal DAPI (6-diamidino-2-phenylindole). 
Ten high power fields were analysed in each section.  Using a grid provided in the 
software the total number of leucocytes and their subpopulation were counted and 
their proportion of the total leukocyte calculated.  
3.3. Results 
Clinical characteristics:  
 
 N=15 
 Age: Mean years.  57 (14) 
Sex (% Male)        60 
Pain to reperfusion time: Minutes(SD) 185 (164) 
Peak Creatinine Kinase U/l(SD)  1348 (11150) 
Peak Troponin I ug/l (SD) 98 (209) 
Total Cholesterol mmol/l (SD) 5.9 (1.1) 
Random Glucose mmol/l (SD) 9.5 (4.5) 
Hypertension %  60 
Hypercholesterolemia  % 40 
Diabetes % 20 
Current Smoking % 40 
Family history of premature CAD  % 20 
Prior Beta Blocker use % 40 
Prior ACE inhibitor use % 60 
Prior Statin Use % 40 
Prior Clopidogrel use % 0 
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3.3.1. Heterogeneity of Thrombus 
 As discussed in section 10.1 the heterogeneity of the thrombus morphology had 
been well described in post-mortem studies where the orientation of the thrombus 
inside the coronary artery is preserved and can be studied in situ. In our study, the 
spatial orientation of the thrombi is lost during aspiration thrombectomy. However, 
as illustrated below, we observed distinct polarisation of the distribution of 
platelets. Some areas of the thrombus revealed dense aggregates of platelets and 
some fibrin while other areas had sparse platelets and abundant   fibrin (fig 3.2-3). 
 
 
 
 
 
                                                          Fibrin-FITC CD42a-PE+ Fibrin-FITC CD42a-PE 
 
 
 
 
 
 
 
 
 
 
 
                                                                  
Figure 3.2: Ex-vivo coronary thrombus & platelet-fibrin heterogeneity: Upper tier Platelet rich, lower tier 
Fibrin rich 
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Intriguingly, the compositional heterogeneity was not restricted to the fibrin and 
platelets alone. We observed that the nucleated white cells also distributed 
heterogeneously along the thrombus.  The areas in close proximity to the platelet 
aggregates also demonstrated aggregates of nucleated white cells. Other regions 
of the thrombus, on the other hand, revealed paucity of nucleated cells and 
presence of dense mesh of fibrin.   
 
 
Green: Fibrin (FITC), Blue: Nuclear signal (DAPI) 
 
Figure 3.3: Ex vivo coronary thrombus 
3.3.1. Phenotyping the white cells involved inside the thrombus  
Since leukocytes are the only cellular component of the thrombus that contains 
DNA, staining the thrombi with the nuclear stain DAPI (4', 6-diamidino-2-
phenylindole) that specifically binds to the DNA identified the leukocyte 
component. The monocytes were identified by expression of the marker CD14, the 
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T lymphocytes by CD3, the B-lymphocytes by CD20 and the neutrophil population 
identified by exclusion (figure 3.4).  
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DAPI +: Total leukocytes 
DAPI + CD14-Cy5+: Monocytes  
 
 
 
 
 
 
 
 
 
 
 
DAPI + CD3-FITC+: T lymphocytes  
 
Figure 3.4: Cell types in thrombus 
 
In the 15 ex vivo coronary thrombi studied granulocytes (DAPI+ CD14- CD3-/ 
CD20-) accounted for 89.5 percent of the leucocytes. The monocytes (DAPI+ 
CD14+) accounted for 10.5 percent of the leukocytes. CD3+ was only very scarcely 
present and no CD20+ B lymphocytes were observed.  
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 The thrombi were stained for expression of CD11b (MaC-1) on the surface of the 
leukocytes. Intense expression of CD11b was observed on almost all leukocytes. 
The leukocytes also stained well for vimentin (figure 3.5).  
    
   
 
 
 
 
 
 
CD11b-PE-Cy5 (Red) + CD41a-Alexa Fluor-350 (Blue)  
 
 
 
  
 
 
 
 
 
 
Vimentin-Alexa Fluor-647 (Red) + Fibrin-FITC (Green)  
 
Figure 3.5: Vimentin expression 
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3.4. Conclusion 
The leukocytes comprise an integral component of the thrombus. Like the 
platelets, the leukocyte distribution within the thrombus was heterogeneous. 
Phenotypically, the leukocytes population resident on the thrombus was 
overwhelmingly granulocytic and less commonly monocytic. They strongly 
expressed CD11b and the intracytoplasmic intermediate filament vimentin. Since 
CD11b can function as a fibrin receptor, the strong expression of this molecule by 
the thrombi leukocytes suggest that these cells may have an import role in 
thrombus formation and stabilisation. 
Although lymphocytes contribute to 30-40% of the total leukocyte population in the 
circulation there was relative paucity of their presence within in the thrombus. The 
under-representation of lymphocytes in the thrombus in this phenotypic analysis 
suggests that the presence of leucocytes is not merely a passive process of 
trapping in the fibrin mesh. Given this lack of evidence however of involvement of 
the cellular lymphocyte adaptive immune system in to the ex vivo thrombus, the 
work of this thesis moved on to focus on the filtrate component of the 
thromboaspirate.      
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 CHAPTER 4: LIQUID PHASE: PLATELETS AND PLATELET 
LEUKOCYTE CONJUGATES 
 
4.1. Background  
 
Increased platelet activity is central to acute athero-thrombotic clinical 
events296,297,298 and is a predictor of cardiac outcomes after myocardial infarction 
(MI).299  Patients with ACS are treated with empirical dual or triple anti-platelet 
therapy, however there are no fully validated clinical tools in routine clinical use to 
measure in vivo platelet function and guide therapy accordingly at this time. This 
empiric antiplatelet strategy has improved the clinical prognosis; however, patients 
with ACS still continue to have a significant incidence of major cardiac events at 4 
to 6 months after hospital discharge.300  
 Platelets are endowed with the potential for homotypic interaction with other 
platelets and heterotypic interaction with leukocytes. This heterotypic interaction 
depends on ligation of CD62p on platelets with PSGL on leukocytes301,302 and is 
subsequently strengthened by GPIb–CD11b ligation,303 fibrinogen bridging of 
platelet GPIIb/IIIa and leukocyte CD11/CD18,304,305 and mutual bridging of CD36 
thrombospondin.306 Monocytes and granulocytes have a greater propensity to 
form conjugates with platelets when compared with the potential of 
lymphocytes.307,308  Activation of platelets can augment the interaction with 
monocytes and neutrophils further309 and circulating platelet–monocyte and 
platelet–neutrophil aggregates are a surrogate marker of platelet activation in 
vivo.310,311  In patients with acute myocardial infarction circulating monocyte -
platelet aggregates can be potentially considered as an early marker of 
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myocardial infarction.312 Relative to the systemic circulation, more monocyte and 
neutrophil-platelet aggregates have been observed at the culprit site of coronary 
artery occlusion during myocardial infarction.313 
On the other hand less than 3% of circulating T lymphocytes is engaged in the 
heterotypic interaction with platelets. Activation of the platelets does not seem to 
enhance this interaction which conversely is augmented by lymphocyte 
activation.311 There is accumulating evidence to suggest that platelets and 
lymphocytes reciprocally modulate each other’s function to promote 
atherogenesis. Platelets facilitate the transmigration of the lymphocyte across the 
endothelium, immobilized platelets   enhance lymphocyte adhesion on the vessel 
wall314,315,316 and platelets promote the infiltration of lymphocytes into the 
inflammatory sites.317 Furthermore, the platelet derived chemokine RANTES 
enhances T cell infiltration318 and is pro-atherosclerotic.319, 320 However, there is a 
paucity of data regarding platelet-lymphocyte conjugates in coronary blood in 
acute myocardial infarction.  
In this chapter we aim to  
1. Evaluate platelet activation in patients with STEMI at the site of plaque rupture 
and in the peripheral circulation.   
2. Evaluate the formation of conjugates with leukocytes in patients with STEMI at 
the site of plaque rupture and in the peripheral circulation.   
4.2. Method  
Twenty paired platelet rich plasma samples were obtained from coronary aspirate 
and femoral arterial blood from patients with STEMI. The platelets were stained 
with monoclonal antibodies against following antigens: CD41a-PerCP (BD 
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Biosciences), CD62P-APC (BD Biosciences) and CD40L-Cy5 (BD Biosciences) 
using parallel isotype control IgG1-PerCP (BD Biosciences), and IgG1-APC (BD 
Biosciences), and IgG1-Cy5 (BD Biosciences) respectively. The mouse anti-
human vimentin (Abcam, MA USA) and its isotype control, mouse antihuman IgG1 
was secondarily conjugated with fluorophore Alexa fluor 647 (Invitrogen) and used 
along with rabbit anti-human PAI-1-FITC and its isotype control rabbit antihuman 
IgM-FITC to evaluate the expression of the vimentin-PAI-1 binary complex.  At 
least 30,000 platelets events were analysed and collected using an appropriate 
density neutral filter. 
Similarly, paired coronary aspirate and femoral arterial blood (n=20) were obtained 
from patients with STEMI while undergoing PPCI. Control sample which included 
femoral arterial blood (n=18) from patients with chronic stable angina undergoing 
coronary angiography or PCI. The decalcified whole blood (EDTA prevents in vitro 
L-P conjugation as CD62P ligation with PSGL-1 is Ca2++ dependent) was diluted 
10X in modified Tyrodes buffer and stained with CD41a-PE (BD Bioscience), CD 
11b-PC5, CD14-FITC, CD3 FITC and nuclear stain Hoechst 33342. The RBCs 
were lysed using lysing solution (BD San Jose, CA, USA). Since the experiments 
were performed and analysis completed within approximately 90 minutes of 
obtaining the samples and the lysing solution contained formaldehyde in it, further 
glutarldehyde fixation was not used to stabilize the platelet-leukocyte conjugates.  
Total leukocyte-platelet conjugates were identified as Hoechst positive nucleated 
cells co-localizing with surface expression of CD 41a. At least 5000 Hoechst 
positive events were analysed and collected in each sample.  
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                            A                                                                B 
Figure 4.1: Co-localization of mono-nucleated white blood cells 
(Hoechst positive events) with platelets (CD41a positive), A: coronary aspirate, B: femoral 
arterial blood. 
 
The leukocyte subpopulations were identified by forward and side scatter 
characteristics, and by using monoclonal antibodies against the surface antigen 
including CD14 as a monocyte marker, and CD3 as a pan T cell marker. Flow 
cytometric analysis as detailed earlier was performed within 1.5 hours of sample 
collection. 
4.2.1. Effect of shear rates 
As discussed in section 2.5.1, the shear rate in the aspiration devise was 
comparatively low we did not anticipate major activation of platelets induced 
artefactually by the shear rates.  To evaluate the effect of shear on formation of  
conjugates, femoral arterial blood samples from 5 subjects with chronic stable 
angina undergoing coronary angiography were obtained and subjected to in-vitro 
aspiration through the Export® XT Aspiration Catheter. The pre and post 
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aspiration samples were stained with CD41a-PE (BD) and Hoechst 33342. The 
total leukocyte- platelets conjugate along with leukocyte subpopulation identified 
on the basis of scatter characteristics were analysed. 
 
Results:    
The mean difference observed between the two sets of experiments was 
calculated and based on this the 95% limits of agreement. 
 
 Pre aspiration (mean) Post aspiration (mean)
Leukocyte-Platelet conjugates 5.5 5.4 
Monocyte Platelet Conjugates 12 12.0 
Lymphocyte-Platelet Conjugates 1.2 1.2 
As can be seen from the table there was no relevant difference attributable to the 
aspiration process.  
  Mean Difference 95% L o A 
Leukocyte-Platelet conjugates 0.08 -0.30 0.46 
Monocyte-Platelet Conjugates -0.04 -0.90 0.82 
Lymphocyte-Platelet Conjugates -0.02 -0.28 0.24 
 
4.2.2. Effect of contrast media 
 
The effect contrast media on formation of leukocyte-platelets conjugate was 
evaluated by serial dilution (125 μl/1.5 ml, 125 μl/1.5 ml, 250 μl/1.5 ml and so forth 
till 1000 μl/1.5 ml) and the leukocyte (and its subpopulations) -platelet conjugates 
were analysed as shown in the figure. Overall there was no significant effect of the 
contrast media on the conjugate formation (figure 4.2).      
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 Figure 4.2: Controlling for contrast media 
 
4.2.3. Reproducibility 
The reliability in measuring leukocyte-platelet conjugates (including the vensection 
and analysis), was evaluated by performing these experiments at an index time 
and repeating the experiments on fresh sample of blood from the same healthy 
volunteers after 2 hours later.   
 
  Index      (mean %) 2 hours  (mean %) 
Total leukocyte-platelet conjugates 4.6 4.7 
Lymphocyte-platelet conjugates 0.5 0.5 
Monocyte-platelet conjugates 6.2 6.1 
Granulocyte-platelet conjugates 4.6 4.3 
The mean difference observed between the two sets of experiments was 
calculated and based on this the 95% limits of agreement. As depicted in the table 
below there was no biologically relevant between the index case and the repeat at 
2 hours.  
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  Mean Difference 95% L o A 
Total leukocyte-platelet conjugates -0.08 -1.02 0.86 
Lymphocyte-platelet conjugates 0.01 -0.62 0.64 
Monocyte-platelet conjugates 0.16 -1.42 1.73 
Granulocyte-platelet conjugates 0.28 -1.00 1.55 
 
4.3. Results 
Clinical characteristics: 
 
 STEMI 
(n=20) 
CSA  
(n=18) 
Age: Mean years.  62 (17) 56 (12) 
Sex (% Male) 75 77 
Pain to reperfusion time: Minutes(SD) 168 (180) N/A 
Peak Creatinine Kinase U/l(SD)  1500 (1380) N/A 
Peak Troponin I ug/l (SD) 98 (239) N/A 
Total Cholesterol mmol/l (SD) 5.1 (1.4) 4.5 (1.4) 
Random Glucose mmol/l (SD) 9 (5) 7 (2) 
Hypertension %  60 50 
Hypercholesterolemia  % 30 38 
Diabetes % 40 22.2 
Current Smoking % 35 27.7 
Family history of premature CAD  % 10 27.7 
Prior Beta Blocker use % 45 72.2 
Prior ACE inhibitor use % 20 61 
Prior Statin Use % 40 88 
Prior Clopidogrel use % 10 27.7 
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4.3.1. Platelet Activation 
Relatively fewer CD41a positive events were observed in the coronary aspirate in 
comparison with femoral arterial blood (p=0.043) when comparatively equivalent 
number of Hoechst 33342 positive mononuclear cells were identified and 
recorded.  
Of the CD41a positive events, there was no difference in surface co-expression of 
CD41a and P-selectin (CD62P) on the platelet between the coronary aspirate and 
the femoral samples (p=0.471).  
In contrast, the platelets expressing CD41a and co-localizing with CD40L, PAI-1, 
and vimentin-PAI-1 binary complex were respectively 32 (13.2, 60.1), 40 (29, 
47.5) and 3.15 (1.4, 10.4) in the coronary aspirate and 22(8.8, 35) (p=0.005), 35 
(27, 46) (p=0.0034) and 1 (0.5, 2.97) (p=0.0001) in the femoral artery (figure 4.3). 
 
 
 
 
Figure 4.3: Comparison of platelet activation markers 
including CD40L, PAI-1, PAI-1-Vimentin complex and CD62 P between coronary 
aspirate and femoral arterial blood 
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 4.3.2. Total platelet leukocyte conjugates 
The following table depicts the total platelet-leukocyte conjugates and relative 
subpopulation analysis of the leukocytes colocalizing with mononuclear white cells 
across the spectrum of coronary disease.  
 
   
N 
 Total L-P 
Conjugates 
Monocyte-platelet 
conjugates 
Granulocyte-Platelet 
Conjugates 
Lymphocyte-
Platelet Conjugates 
Intracoronary 20 15.1 (9, 25) 42.4 (33, 60) 4.4 (2.6, 9) 20  (13, 30)  
STEMI Femoral  20 3.9 (2, 7.2) 23.6 (19, 35) 2 (1.35, 2.85) 10 (7, 15) 
Chronic stable Angina 18 3.9 (2.9, 5) 14 (10, 25) 1.4 (.55, 2) 1.1 (1, 1.4) 
 
 
4.3.2.1. ST elevation myocardial infarction (platelet-all leukocytes). 
 
Of the mononuclear cells positive for nuclear stain Hoechst, 15.1 (9, 25) cells in 
the coronary aspirate and 3.95 (2, 7.2) cells in the femoral blood co-localized with 
CD41a, p=0.0001 (figure 4.4).    
 
 
 
Figure 4.4: Total platelet leukocyte conjugates 
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4.3.1.3. Chronic stable angina (platelet-all leukocytes) 
 
The percentage of the leukocytes in peripheral circulation engaged in forming 
conjugates with platelets was 3.9 (2.9, 5). This was not significantly lower than the 
degree of conjugate formation in femoral arterial blood of patients with STEMI 
(figure 4.4) 
4.3.3. Platelet monocytes Conjugates 
               
       
               
                                  A                                                                        B 
Figure 4.5: Platelet monocyte conjugates (FACS) 
(Q2 population) in Coronary Aspirate A, Femoral Artery B:  the monocytes are identified 
as the purple coloured cell population on the scatter plot. 
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 4.3.3.1. ST elevation myocardial infarction (platelet-monocyte)  
 
There was no difference in percentages of mononuclear cells expressing the 
monocyte phenotype marker, CD14, between the coronary aspirate and femoral 
blood (p=0.55)).  In the coronary aspirate, 42 (33, 60) of the monocytes co-
localized with platelets expressing CD41a, in contrast to the 23.6 (19, 35) in 
femoral artery (p = 0.0003) (figure 4.6).  
 
Figure 4.6: Platelet monocyte conjugates (summary) 
 
4.3.3.3. Chronic stable angina (platelet-monocyte) 
 
 In stable coronary disease, 14 (10, 25) of the monocytes in peripheral arterial 
circulation formed aggregates with platelets in contrast to the 23.6 (19, 35)   in the 
femoral arterial blood of patient with STEMI, p=0.03 (figure 4.6). 
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4.3.4. Granulocyte-Platelet Conjugates 
4.3.4.1. ST elevation myocardial infarction (platelet-granulocyte)  
 
The granulocytes were identified by forward and side scatter characteristics and 
by exclusion of CD3 and CD14 positive mononuclear cells. There was no 
difference in total percentages of the granulocytes between the coronary aspirate 
and femoral blood (p= 0.8).  In the coronary artery, 4.4 (2.6, 9) of the granulocytes 
formed conjugates with platelets expressing CD41a, compared with 2(1.3, 2.8) in 
femoral artery. (p= 0.0005).  
4.3.4.3. Chronic stable angina (platelet granulocyte) 
 
 In CSA, 1.4 (0.55, 1.9) of the granulocytes formed aggregates with platelets in 
peripheral arterial circulation.  
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 4.3.5. Lymphocyte-Platelet Conjugates 
                     Coronary Blood                                                  Femoral Blood 
                  
 
 
 
                   
 
 
 
            
 
 
 
 
 
                                                                                                            
 
 
 
 
 
 
 
 
 
 
 
 
                     
 
 
                                A                                                                      B 
Figure 4.7:  Lymphocyte-platelet conjugates (FACS) 
(Q2 population) in Coronary Aspirate A, Femoral Artery B:   the lymphocytes are 
identified as the discreet cell population on the top left hand corner in the scatter 
plot 
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 4.3.5.1. ST elevation myocardial infarction (platelet-lymphocyte)  
 
 There was no difference in percentages of mononuclear cells expressing the pan 
T cell marker CD3 between the coronary aspirate and femoral blood (13.5 versus 
14.9 p=0.17). However, 20 (13.5, 30) of T lymphocytes in the coronary artery, and 
10 (7, 15.5) in the femoral artery co-localized with CD41a (p=0.0003) (figure 4.8).  
 
 
 
 
Figure 4.8: Platelet lymphocyte conjugates (Summary) 
 
Since the kinetics of lymphocyte-platelet interaction in vitro is slower than the 
monocyte–platelet conjugates, a longer duration of interaction would result in 
higher degree of conjugates formation. To evaluate whether longer duration of 
coronary occlusion would promote higher lymphocyte-platelet interaction, we 
correlated the duration between onsets of pain to reperfusion with the percentage 
of CD3 positive cells co-localizing with CD41a positive platelets. We found that 
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there was a weak but statistically significant association between the pain to 
reperfusion times and the lymphocyte-platelet conjugates (r2 =0.241, p=0.032) 
(figure 4.9).    
 
 
 
 
 
 
 
 
 
Figure 4.9: Time and lymphocyte platelet conjugates 
 
4.3.5.2. Chronic stable angina (platelet lymphocyte) 
 
 In femoral arterial blood of patients with chronic stable angina, 2.0 (1.1, 2.6) of the 
lymphocytes expressing CD3 were co-localized with platelets expressing CD41a. 
This level of heterotypic interaction was significantly less when compared to the  
level in femoral blood of patients with STEMI (p< 0.0001)          
4.4. Conclusion 
4.4.1 Platelet activation markers 
The reduction in CD41a positive events in the coronary aspirate in comparison 
with the femoral arterial blood sample in patients with STEMI probably reflects 
consumption of the platelets within the thrombus and their association with the 
leukocytes to form the conjugates.  
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Expression of CD62 (P-selectin) at the platelet surface is often used as a general 
marker of platelet activation.321  CD62 expression is enhanced in patients with 
acute coronary syndromes.322 It was surprising that the degree of expression of 
CD62P in the platelets obtained from coronary aspirate of patients with STEMI, 
which conventionally is regarded as marker of platelet activation, was not different 
from the platelets obtained from femoral artery. However, the expression kinetics 
of the various inducible markers of the platelets can vary temporally. The P 
selectin expression is rather transient and probably explains why the CD62P 
expression in the coronary aspirate is not significantly different than the peripheral 
circulation. Conversely, CD40L has longer expression kinetics323 and may explain 
the differential expression between the coronary aspirate and the femoral artery.  
Ultimately however the magnitude of the differences was small. 
4.4.2 Platelet conjugates 
It is perhaps not surprising that the total platelet leukocyte, platelet-monocyte, 
platelet-granulocyte and platelet lymphocyte conjugates in the coronary 
thromboaspirate were elevated, and our findings confirm observations made by 
other groups.324 However, further research is required to elucidate whether these 
complexes have any pathogenic role in either the physical generation of occlusive 
coronary thrombus or subsequent microvascular and or myocardial damage 
occurring during the reperfusion process.  
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CHAPTER 5: LIQUID PHASE: ACTIVATED, PROINFLAMMATORY AND 
REGULATORY T LYMPHOCYTES 
 
5.1. Background 
In addition to the initiation and progression of atherosclerosis, accumulating 
evidence suggest that T cells may also exert a coronary plaque destabilizing effect 
which is important in the pathogenesis of acute coronary syndromes. Although 
these acute phenomenona are attributable to the instability of an index culprit 
plaque, studies have reported synchronous diffuse destabilisation of 
atherosclerotic plaques in patients with acute myocardial infarction, begetting the 
concept of "pan-coronaritis".325,326,327,328  The underlying putative mechanism 
driving this systemic inflammation may included exogenous microbial components 
as discussed earlier or autologous proteins for instance, B-2 GP-1, oxidised LDL 
(oxLDL), and stress or heat shock proteins (HSP). These trigger factors may lead 
to activation of immune cells perpetuating and propagating the inflammatory 
process. A transient burst of T-cell activation can be detected systemically in 
patients with acute coronary syndromes.329 
Regarding specifically proinflammatory T cells, acute coronary syndromes are 
accompanied by oligoclonal expansion of a repertoire of CD4+ T cells in the 
peripheral circulation that have lost the surface expression of co-stimulatory 
molecule CD28. Although the pathogenic potential of this subpopulation of CD4 T 
cell is well elucidated in vitro, there is paucity of knowledge pertaining to their 
phenotypic characteristics and their relative distribution between the peripheral 
circulation and target site of inflammation. Whilst augmentation of the pro-
inflammatory T cells may be important in orchestrating the atherosclerotic 
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process, the attenuation of immune modulating cells like Tregs may also exert 
permissive effect in progression of the atherosclerosis. In Humans Tregs has been 
demonstrated in peripheral blood of subjects with normal coronary arteries330 and 
are decreased in the peripheral blood of patients with acute coronary 
syndromes.331,332 Furthermore, the frequency of Tregs in atherosclerotic lesion 
was found to be attenuated and constituted only 0.5–5% of the total number of 
CD3 + T cells.333 Tregs are subset of CD25+ CD4+ T cells   and express lineage 
specific marker FOXP3 (Forkhead Box Protein P3), a member of the forkhead 
winged helix protein family of transcription factors.334,335   
Simultaneous sampling of lymphocytes in the liquid phase of the aterothrombotic 
aspirate at the target site of inflammation (the culprit atherosclerotic lesion) and 
peripheral circulation of patients with acute myocardial infarction may provide 
further mechanistic information with regard to the involvement of lymphocytes in 
acute coronary syndromes. In this series of experiments we aim to evaluate the 
extent of T cell activation, the degree of expansion of the proinflammatory CD4+ 
CD28null T cells including memory phenotypes and the regulatory T cells 
expressing the immunoregulatory FOXP3+.  
5.2. Method  
5.2.1. Activated intracoronary and peripheral T lymphocytes. 
Paired intra-coronary liquid phase aspirate and femoral arterial samples (n=20) 
from patients with STEMI were obtained during PPCI and femoral arterial blood 
(n=20) from patients with chronic stable angina undergoing coronary angiography. 
The samples were stained as whole blood preparation as detailed above using a 
panel of monoclonal antibodies and matching isotype control in parallel:  
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Test                                                           Isotype 
CD3-FITC                                                 IgG2a-FITC 
CD40L-PC5                                              IgG1-PC5 
HLA-DR-PerCP                                        IgG2a-PerCP 
CD14-FITC                                               IgG1-FITC 
CD11b-PC5                                              IgG1-PC5 
The leukocyte population was gated and 5000 events recorded after appropriate 
electronic compensation.  
5.2.2. Proinflammatory CD4+ CD28null T lymphocytes 
Paired coronary aspirate and femoral arterial blood from patients with STEMI 
(n=22) femoral arterial blood from chronic stable angina (n=20), and peripheral 
venous blood from healthy volunteers (n=10) were stained as a whole blood 
preparation using following antibodies: CD4-PE, CD62L-APC, CD45RO-CY7, 
CCR7-FITC, and CD28-PC5.  The lymphocyte population was identified by side 
and forward scatter and were gated to exclude debris and aggregates. The 
lymphocyte population expressing the CD4 was gated to evaluate for the 
expression of CD28 molecule. The CD4+CD28+ and CD4+CD28null T cell 
population were both dichotomised on the basis of expression of phosphatase 
CD45R0 in to naïve and memory CD4+CD28null T cells. These cell populations 
were then interrogated for expression of adhesion molecules CD62L and CCR7 to 
classify them into TEM and TCM. (Figure 5.1)  
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                                                        A                                                                                 B 
 
Figure 5.1: Multichannel multicolour flow cytometry for CD4+ CD28null T lymphocytes 
A: intracoronary Aspirate, B: Femoral Artery. P1: Total Leukocytes P2: Total 
Lymphocytes P3: Total CD4 T Lymphocytes P4: CD4+ CD28null T Lymphocytes   P12: 
Memory CD4 T Lymphocytes P4:CD4+ CD28null T Lymphocytes, Q2 and Q4: Central 
Memory CD4 T Lymphocytes P4:CD4+ CD28null T Lymphocytes, Q1 and Q3: Effector 
Memory CD4 T Lymphocytes P4:CD4+ CD28null T Lymphocytes. 
 
5.2.3. Intracytoplasmic flow cytometry for FoxP3 expression.  
Mononuclear cells were isolated from the coronary filtrate and the femoral arterial 
blood by gradient centrifugation as described earlier. 0.5-1×106 of the 
mononuclear cells at concentration of 1X106/ml was taken in to paired falcon 
tubes. 2ml of flow Cytometry Staining Buffer (PBS) was added to the tube, 
centrifuged for 6 minutes at 1500 rpm, and the supernatant discarded. The cells 
were stained with 20 μL of antihuman CD4- PE (BD Bioscience, San Jose CA, 
USA) and IgG1-PE isotype (Beckman coulter) and incubated at room temperature 
for 20 minutes. The cells were washed in PBS and centrifuged again at 1500 rpm 
for 5 minutes.  The pellet was re-suspended in 750 μL of fixation/permeabilization 
working solution (eBioscience), incubated at 4 °C for 45 minutes and subsequently 
washed twice with 2ml of 1x permeabilization Buffer (eBioscience). The cells were 
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blocked with 2μl normal rat serum at 4°C for 15 minutes. Without washing after 
blocking step, 10 μl of anti-FOXP3-FITC antibody (eBioscience) was added and 
incubated at 4°C for 30 minutes. The cells were washed again with 2ml of 1× 
permeabilization Buffer, Centrifuged and supernatant decanted. To label 
leukocytes, Hoechst 33342 (Molecular Probes, Eugene, OR, USA), diluted in PBS 
(1 µg/L final concentration), was added and analysed in FACS after 30 min. 
 
 
 
 
 
 
 
                
 
                         
                                       
 
 
 
 
 
 
 
                                      A                                                                  B 
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 Figure 5.2: Intracytoplasmic flow cytometry 
A: intracoronary Aspirate, B: Femoral artery. P4: Total CD4+ T lymphocytes, Q2: 
CD4+ FOXP3+ T lymphocytes 
5.3. Results 
Clinical characteristics:  
 
 STEMI 
(n=22) 
CSA  
(n=20) 
Healthy  Volunteer 
(n=10) 
Age: Mean years.  59 (15) 54 (12) 30 (4) 
Sex (% Male) 70 80 50 
Pain to reperfusion time: Minutes(SD) 165 (174) N/A N/A 
Peak Creatinine Kinase U/l(SD)  1216 (1038) N/A N/A 
Peak Troponin I ug/l (SD) 80 (229) N/A N/A 
Total Cholesterol mmol/l (SD) 4.9 (1.1) 4.5 (1.4) N/A 
Random Glucose mmol/l (SD) 10 (5) 7 (2) N/A 
Hypertension %  54 60 0 
Hypercholesterolemia  % 31 40 0 
Diabetes % 27 30 0 
Current Smoking % 33 25 0 
Family history of premature CAD  % 22.7 25 0 
Prior Beta Blocker use % 22.7 70 0 
Prior ACE inhibitor use % 25 65 0 
Prior Statin Use % 31.9 90 0 
Prior Clopidogrel use % 0.9 25 0 
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5.3.1.1. Activated intracoronary  T- lymphocyte in STEMI 
 
 There was no difference in number of mononuclear cells expressing the pan T 
cell marker CD3 between the coronary aspirate and femoral arterial blood , 10.9 
(9, 16.8) versus 11.5 (7.25, 15.75 ), p=0.638.  However, 28.55 (16, 48) of CD3 
positive cells in the coronary aspirate and 17.85 (8, 229) percentage in the femoral 
blood (p=0.0001) expressed CD40L. Similarly, 36.55 (19, 48) and 17 (12, 21) 
percentage of the CD3 T cells respectively expressed MHC class 2 antigen HLA-
DR (p=0.0004) (Figure 5.3). In contrast, CD14 positive monocytes ( 6.6% versus 
6.5%, p=0.65) and co-expression with Mac-1 (85.3% versus 88.6% p=0.60) and 
HLA-DR (90.3% versus 88.6%, p=0.45) did not differ significantly in coronary 
aspirate and femoral blood. Figure 5.3 
 
Figure 5.3: Activated T-Lymphocytes in STEMI 
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 5.3.1.2. Activated peripheral T lymphocyte in Chronic Stable Angina  
 
 In the femoral artery of patients with chronic stable angina, 13% of the 
mononuclear cells expressed CD3.  Median of 6.5 (8.5, 16) and 16 (9, 23) of the 
CD3 positive cells expressed CD40L and HLA-DR respectively.  
5.3.2. Proinflammatory CD4+ CD28null T cells across the spectrum of 
Coronary Artery Disease  
5.3.2.1. ST Elevation Myocardial Infarction (CD4+ CD28null ) 
 In patients with STEMI, 33 (29, 39) and 35 (28, 42) of lymphocytes, identified by 
their forward and side scatter characteristics, expressed CD4+ in coronary aspirate 
and femoral arterial blood respectively (p= 0.352). Of the CD4+ T cells, 48% (26, 
68) in coronary aspirate and 31% (13, 52) in femoral blood were negative for 
surface expression of CD28 molecule (p=0.0005) (Figure 5.4).   
 
5.3.2.2. Chronic Stable Angina (CD4+ CD28null ) 
 
Although the total percentage of CD4 T cells in femoral arterial blood of age 
matched patients with chronic stable angina was similar to the patients with 
STEMI (mean age 54 years versus 59 years); significantly fewer CD4+ T cells 
demonstrated the loss of surface expression of the CD28 molecule: 12 (10, 18),   
p = 0.0102 (Figure 5.4).    
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Figure 5.4: Proinflammatory (CD4+ CD 28 null) Lymphocytes 
In STEMI and stable coronary disease 
5.3.2.3. Healthy Volunteers (CD4+ CD28null ) 
 
Only 3 (2, 5) of the CD4+ T cells in young healthy volunteers (mean age 32) were 
CD4+ and CD28null T cells.   
5.3.3.1 Naïve versus memory CD4+ CD28null T cells 
 
In patients with STEMI, 44 (19, 62) of the CD4+ CD28null cells in femoral artery 
expressed CD45RO indicating a memory phenotype in contrast to 29 (15, 50) in 
coronary aspirate (p=0.0083) (Figure 5.5).  
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Figure 5.5: CD4+ CD28null cells expressing memory T cell marker CD45RO. 
 
5.3.3.2 Memory subsets of proinflammatory T cells (CD4+ CD28null )  
 
 
Central memory cells: Similarly, 74 (50, 86) of the CD4+ CD28null memory T cells 
(CD45RO+) in the femoral artery and 43  (29,70) of the CD4+ CD28null memory T 
cells in the coronary aspirate expressed the phenotypic marker of central memory 
T cells (CCR7+) (p=0.0017).  
Effector memory cells: Conversely, 26 (13, 45) and 56 (30, 71) of the CD4+ 
CD28null memory T cells expressed the phenotypic marker of effector memory T 
cells (CCR7-) in the femoral and coronary aspirate respectively (p=0.0034). 
Further, phenotypic characterization of the   CD4+ CD28null memory T cells and 
comparison with CD4+ CD28+ memory T cells is depicted in the following table 
(Table 5.1). The phenotypic subanalysis of the CD 4 28 null cells is depicted in 
figure 5.6 
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 Femoral Blood  Coronary Aspirate  P 
CD4+CD28-CD45RO+ CCR7+ CD62L+ 36.4  (18, 46) 25  (15, 35) 0.01 
CD4+CD28+CD45RO+ CCR7+ CD62L- 33.3   (18, 50) 12 (8, 28) 0.05 
CD4+CD28-CD45RO+ CCR7- CD62L+ 8  (3, 13) 19  (7, 34) 0.11 
CD4+CD28-CD45RO+ CCR7- CD62L- 17   (3, 22) 24  (11, 50) 0.002 
CD4+CD28+CD45RO+ CCR7+ CD62L+ 57  (50, 70) 54  (40, 66) 0.141 
CD4+CD28+CD45RO+ CCR7+ CD62L- 22   (13, 40) 19   (12, 33) 0.441 
CD4+CD28+CD45RO+ CCR7- CD62L+  4  (2, 17) 7  (4, 15) 0.802 
CD4+CD28+CD45RO+ CCR7- CD62L- 3   (2, 7) 8  (2, 13) 0.091 
 
Phenotypic subanalysis of the CD4+ CD28null memory T (CD45RO+) lymphocytes 
Based on surface of expression of the homing molecules CD62L and CCR7 
 
Femoral Artery 
Coronary Aspirate    
 
Figure 5.6: Phenotypic subanalysis of the CD4+ CD28null memory T (CD45RO+) lymphocytes 
Based on surface of expression of the homing molecules CD62L and CCR7. TCM: Central 
memory  Tcells, TEM: Effector  memory  T cells 
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5.3.4. Immune modulatory FOXP3+ Tregs in STEMI  
 
Intracytoplasmic flow cytometry was performed in mononuclear cells present in 11 
paired coronary aspirates and femoral arterial blood. The mean proportion of the 
mononuclear cells expressing CD4 did not differ between the coronary aspirate 
and the femoral artery.  Of CD4+ T cells, a median of 10 (7, 12)%   in the femoral 
blood expressed FOXP3 in contrary to 6 (3,6) of the CD4+ T cells in the coronary 
artery (p=0.0036) (Figure 5.7). 
 
 
Figure 5.7: Immunoregulatory FOXP3 expression 
5.4.  Conclusion  
These experiments demonstrated relatively higher expression of CD40L, a marker 
of antigen specific T cell activation and HLA-DR, a marker of non-specific T cell 
activation, at the culprit site of an infarct related artery than in the femoral artery of 
patients with STEMI. One of the most interesting observations was that there were 
increased numbers of CD4+ CD28null T lymphocytes in the liquid phase coronary 
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aspirate when compared with femoral blood.  There were relatively fewer FOXP3+ 
regulatory T cells at the index culprit site of plaque rupture compared to the 
peripheral circulation in patients with ST elevation myocardial infarction.  
These findings suggest that augmented proinflammatory and attenuated 
immunomodulatory T lymphocytes may be associated with atherosclerotic plaque 
instability.  
The circulating CD4+CD28null cell population is amplified in acute coronary 
syndromes and constitutes up to 30-50 percent of total CD4+ T cell population,336 
and their frequency predicts the risk of recurrence of acute coronary events.337 To 
our knowledge this is the first time the intracoronary CD4+CD28null cell population 
had been studied in this manner.  The CD4+ CD28null T lymphocytes have been 
shown previously to have cytolytic potential against endothelial cells338 and their 
release downstream into the myocardium during primary angioplasty may help to 
explain the phenomenon of distal microvascular and myocardial damage during 
reperfusion in STEMI.   Regarding memory cell types, the differences observed 
were modest, however whilst there were relatively fewer memory type 
CD4+CD28null cells in the coronary than femoral artery, phenotypic sub analysis 
of CD4+CD28null memory (CD45RO) cells indicated a greater proportion of 
effector than central memory cells in the coronary than femoral artery. Since  
One of the mechanism of genesis of the effector memory cell is exposure to its 
cognate antigen and has homed to target site of inflammation thus losing their 
homing receptor CCR7, these cells if found at higher concentration at site of 
inflammation may indicate that they have tropism for that particular site. In our 
experiment we clearly demonstrated a clear gradient in the number of the effector 
memory phenotype CD4+28null cells between coronary and femoral artery 
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samples, thus indicating that they have been released from the ruptured 
atherosclerotic plaque as they have already homed to their cognate site of 
inflammation, rather than generated locally in the arterial lumen during the 
thrombotic process, or ‘enmeshed’ in the clot whilst circulating. Thus coronary 
thromboaspirate could potentially yield cells from an unstable plaque potentially 
facilitating the study of factors associated with plaque instability. 
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CHAPTER 6:  LIQUID PHASE- REACTIVE ANTIBODIES 
 
6.1. Background 
 
Many organ specific autoimmune diseases are associated with accelerated 
atherosclerosis and increased cardiovascular mortality.339,340 The complement 
system also plays a pivotal role in initiation and propagation of inflammation and 
evidence suggests that atherosclerosis is no exception. Complement activation is 
known to occur during acute myocardial infarction.341 This activation inflicts 
inflammatory damage,342,343 is associated with larger infarct size,344 and predicts 
poor clinical outcomes.345  The accumulation of terminal complement complexes 
in ischemic myocardium early during the reperfusion suggests its involvement in 
reperfusion myocardial damage.346  
Although there is substantial research in to the role of cell-mediated immunity in 
atherosclerosis and there is evidence of its alteration during acute coronary 
syndromes, there is relatively less data regarding the involvement of humoral 
immunity during acute coronary syndromes.  We aimed to evaluate the presence 
of autoantibodies in the liquid phase coronary thromboaspirate of patients with 
acute myocardial infarction using complement mediated cytotoxicity and apoptosis 
assays. 
6.2. Method  
6.2.1. Complement Dependent Cyototoxicity (CDC) 
6.2.1.1. Methodological principle:  
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All sera were screened for auto-reactive antibodies by a modified microcytotoxicity 
technique.347 A panel of viable HLA-typed lymphocytes were incubated with 
patient’s sera so that antibodies present in the serum bind with the target antigen 
expressed on the surface of the lymphocytes.  When rabbit complement is added, 
the antibody attached to the cell surface activates the classical complement 
pathway, leading to the production of the membrane attack complex of the 
complement (C5-9), which ultimately causes cell lysis. The cell lysis was assessed 
by viability staining using combination of fluorescent stains ethidium bromide and 
acridine orange. CDC assays are able detect both IgG and IgM by using 
dithiothreitol (DDT). DDT cleaves disulphide bonds, and because IgM contains 
significantly more than IgG, the IgM reactivity is preferentially degraded. In 
addition, IgM non-HLA auto-reactive antibodies can be detected on this assay. A 
patient was considered to be antibody positive if panel reactivity was greater than 
5% and the strength of reaction was greater than 10% above background levels. 
6.2.1.2. Procedures 
 
Twenty six paired coronary and femoral sera were tested using an HLA Class I (A, 
B, C) and Class II (DR and DQ) typed panel of peripheral blood mononuclear cells 
(PBMC) from 10 healthy volunteers.1 μl of the paired coronary and femoral sera 
with 0.5% phenol red was coated in duplicates into the terasaki plates. 1μl of AB 
serum, IgG control and IgM control respectively were introduced in to the wells of 
row 1 as shown below (Figure 6.1) 
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Figure 6.1: Terasaki plate 
1μl of DTT and PBS were added to the alternate column. 1μl of the PBMC cell 
suspension were added in to the wells and incubated at 22°C for 60 minutes. 5μl 
of the lyophilised rabbit complement (Cedarlane Laboratories, Canada) dissolved 
in PBS/cystine was added to each well using an HLA microsyringe multiple 
dispenser and incubated for a further 120mins.   
Cell viability was assessed by the addition of 5μl of Fluoroquench in to the wells 
and observation under a fluorescent microscope in which viable cells fluoresce 
green and dead cells orange/red. The viability of cells in each well was assessed 
using the following scale: (figure 6.2a-c)  
0 = Negative  
1 = 10-20% cell death - doubtful positive  
2 = 21-40% cell death- weak positive              
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4 = 41-60% cell death- weak positive  
6 = 61-80% cell death- strong positive  
                          8 = 81-100% cell death- strong positive 
                     
Figure 6.2a Negative control: 
Viable cells 
Figure 6.2b Positive control: 
Dead cells 
 
 
                                        
Figure 6.2c Test: Weak positive 
 
Figure 6.2 Cell viability 
 
6.2.2. Apoptosis assay 
6.2.2.1. Principles 
 
The complement dependent cytotoxic assay dichotomises target leukocytes into 
binary viable or dead cell populations, and this assay is not sensitive enough to 
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identify those cell populations that are undergoing apoptosis or are partially dead. 
Furthermore, reactive antibodies against target cell populations other than 
lymphocytes are not assessed in the CDC assay.   We therefore incubated the 
paired coronary and femoral sera in presence of rabbit complement to induce 
complement dependent cell injury as a more sensitive assay of cell damage.    
The induction of apoptosis and cell death was assessed by flow cytometry after 
double staining with annexin V and propidium iodide.  
6.2.2.2. Procedures 
 
 Buffy coat preparation for leukocytes from blood of healthy volunteers was 
prepared as detailed in chapter 2.6.2.  Approximately, 106 cells dissolved in 50 μl 
of RPMI were taken in falcon tubes and incubated with:  
Positive control: 50 μl of positive antibody 
Positive control2: 50 μl 10% formaldehyde (Sigma)  
Negative control: 50 μl of AB serum 
Test 1: 50 μl of intracoronary plasma 
Test 2: 50 μl of femoral arterial plasma 
 
The samples were incubated at 37 °C for 60 minutes. Subsequently of 50 μl 
lyophilised rabbit complement (Cedarlane Laboratories, Canada) was added in to 
each tube and they were further incubated at 22 °C for 60 minutes. 
The cells were then suspended in ice cold RPMI and centrifuged at 500 X g for 5 
minutes at 4°C. The supernatant were discarded and the cells suspended in 100 
μl of 1X Binding Buffer (Beckman Coulter, Marseille, France).  
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1 μl of annexin V-FITC (Beckman Coulter) and 5 μl of propidium iodide (Beckman 
Coulter, 250 μl dissolved in 1ml of 1X Binding Buffer) were added in the cell 
suspension and incubated at dark 4 °C for 15 minutes. The cells were further 
diluted in 400 μl of 1X binding buffer and analysed in flow cytometer (Beckman 
coulter) within 30 minutes.   
6.3. Results 
Clinical Characteristics: 
 STEMI 
(n=26) 
Age: Mean years.  62 (15) 
Sex (% Male) 69.9 
Pain to reperfusion time: Minutes(SD) 168 (180) 
Peak Creatinine Kinase U/l(SD)  1500(1013) 
Peak Troponin I ug/l (SD) 78 (283) 
Total Cholesterol mmol/l (SD) 5.9 (1.3) 
Random Glucose mmol/l (SD) 8 (4) 
Hypertension %  50 
Hypercholesterolemia  % 31 
Diabetes % 27 
Current Smoking % 33 
Family history of premature CAD  % 31.8 
Prior Beta Blocker use % 31.8 
Prior ACE inhibitor use % 19 
Prior Statin Use % 31 
Prior Clopidogrel use % 7.7 
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6.3.1. CDC microassay  
Of the 26 pairs of coronary and femoral samples analysed, 11.1% of the coronary 
aspirate (2/26 weakly positive and 1/26 strongly positive) and 3.5% of the femoral 
(1/26 weakly positive) induced significant PBMCs death indicative of the presence 
of IgM non-HLA antibody.  
  
6.3.2. Apoptosis assay  
Thirteen paired coronary and femoral sera were incubated with the buffy coat 
leukocytes in the presence of rabbit complement.  After 2 hours of incubation, a 
mean of 9.5 (10.5, 7.5) of leukocytes incubated with coronary sera and 5.2 (2.5, 9) 
leukocytes incubated with femoral sera were positive for the apoptosis marker 
annexin V (p<0.001). This suggests the presence of more reactive antibodies in 
the coronary than femoral sera, which bind to the leukocyte cell surface and 
activate the complement system (Figure 6.3a).   
     
 
 
Figure 6.3a: Apoptotic cells 
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 Figure 6.3b: Viable cells 
 
Figure 6.3c: Dead cells 
The median magnitude of leukocytes that were viable (annexin V negative and 
propidium iodide negative) after incubation with coronary sera compared to that 
following incubation with femoral sera was respectively 82 (76, 84) and 86 (84, 
87), p=0.04 (Figure 6.3b). There was no difference in the cell death (annexin V 
positive and propidium iodide positive) induced by the coronary versus femoral 
sera 4. 2 (3, 6) versus 3.8 (3, 5) respectively, p=0.4) (Figure 6.3c). 
To ascertain whether the apoptosis was induced by the effect of the rabbit 
complement alone, the leukocytes were incubated in absence of the patient’s 
serum but with serial concentration of the rabbit complement (1 RPMI: 1 rabbit 
complement to 1 RPMI: ¼ rabbit complement). The median of the leukocytes 
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showing apoptosis (positive for annexin v and negative for propidium iodate) was 
0.8% in contrast to 9.5% and 5.2% showing apoptosis when incubated with 
coronary and femoral sera respectively (Figure 6.4).   
 
Figure 6.4: Apoptosis with Rabbit complement alone 
6.4. 4. Conclusion 
The CDC assay suggested the presence of autoreactive non-HLA IgM antibody 
more frequently in the sera derived from the coronary aspirate of patients with 
acute myocardial infarction when compared with the sera of peripheral circulating 
blood. The sensitivity of CDC assay is however limited since it dichotomises the 
target cell population into binary viable and dead cells. When similar experiments 
were repeated using the more sensitive assay of annexin V and propidium iodide 
as markers of complement dependent cell injury the apoptosis inducing effect of 
the serum was amplified (though there was little change in viability or death). This 
suggests that there may be a higher concentration of reactive IgM in the liquid 
phase of the coronary thromboaspirate than in the femoral artery during 
myocardial infarction.  
Complement is known to be deposited on cardiomyocytes after myocardial 
infarction and IgM can fix complement initiating the classical cascade culminating 
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in formation of membrane attack complex. Although the positive findings of this 
series of experiments were limited to apoptosis, liquid phase reactive antibody 
may have a role in the pathogenesis of myocardial injury following reperfusion in 
acute myocardial infarction due to downstream release at the restoration of flow.  
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 CHAPTER 7:  VIMENTIN AND ANTIVIMENTIN ANTIBODIES 
 
7.1 Background 
 
Vimentin is a highly conserved intermediate filament protein expressed 
intracellularly in cells of mesenchymal origin including endothelial cells.  However, 
cellular activation348 or apoptosis can induce surface expression of these 
proteins.349,350  Apoptotic cells are an important source of autoantigens.351,352 
Previously, injection of apoptotic cells into normal mice resulted in production of 
various autoantibodies including antivimentin autoantibodies.353 Autoantibody 
against vimentin is an independent predictor of transplant associated coronary 
artery disease.354 However this antibody has not been evaluated in atherosclerotic 
ischemic heart disease.  
7.2 Methods: ELISA for Antivimentin antibodies 
The antivimentin antibodies were measured at Professor Marlene Rose`s 
Laboratory at Harefiled Heart science centre. The lab is certified for measuring 
antivimentin antibody for clinical purpose.  The ELISA procedure uses both 
positive and negative controls to ensure that there is no cross reaction between 
vimentin and other proteins.  100 μl of vimentin (1mg/ml) was coated overnight 
into the rows B, D F and H of 96 well ELISA plates.  The plates were blocked with 
5% non-fat dried milk (Marvel, Ireland) in PBS, 0.1% Tween-20 (200 μl Milk/PBST) 
at 22 °C for 60 minutes. Subsequently, flicking in to the sink and striking the plate 
on to the towel for at least five times discarded the solution.  
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Serial dilutions of the positive vimentin control were prepared by taking 5 X 2ml 
tubes. To the first, 1000 μl and to the next four, 500 μl of the blocking solution was 
added. To the first tube 20 μl of positive vimentin control was added and vortexed. 
500 μl of the mixture was transferred to the second tube and vortexed. Similarly 
500 μl of the mixture was transferred from the second in to the third and so forth. 
The negative control was prepared by mixing 10 μl of negative serum with 500 μl 
of blocking solution and similarly 10 μl of the test serum was mixed with 500 μl of 
the blocking solution. These samples were introduced in the ELISA plate as per 
the following design (figure 7.1): 
A1, A2, B1, B2: 100 μl of negative control 
A3, A4, B3, B4: 100 μl of 1/50 dilution positive control 
A5, A6, B5, B6: 100 μl of 1/50 dilution positive control and so on 
C1, C2…. H12:   test sera                                                           
 
Figure 7.1: ELISA plate 
The plate was incubated at 22 °for 60 minutes and the fluid was decanted off. The 
plate was washed using 200 μl PBS/Tween 1% 5 times. The Horseraddish 
peroxidase conjugated to rabbit anti-human IgM antibody (Dako Corp, CA) was 
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diluted to 1/100 and 100 μl was added into each well, incubated for 45 minutes 
and washed 5 times.  
The colorimetric solution was prepared by dissolving a 1 mg tablet of TMB 
(Tetremethylbenzidine dihydrochloride, Sigma, UK) in to 9ml of distilled water, 5 μl 
of hydrogen peroxide and 1 ml of 10X phosphate-citrate buffer.  50 μl of the 
reagent was added to each well and the ensuing chromogenic reaction was 
allowed to develop for 3 minutes before being terminated by adding 50 μl of 
sulphuric acid in to each well.  The absorbance was read on ELISA reader 
(Thermo Scientific) at 450 nm. The antibody titres were expressed as titre units.  
7.3 Results 
Patient Characteristics: 
 STEMI 
(n=26) 
Age: Mean years.  62 (15) 
Sex (% Male) 69.9 
Pain to reperfusion time: Minutes(SD) 168 (180) 
Peak Creatinine Kinase U/l(SD)  1500(1013) 
Peak Troponin I ug/l (SD) 78 (283) 
Total Cholesterol mmol/l (SD) 5.9 (1.3) 
Random Glucose mmol/l (SD) 8 (4) 
Hypertension %  50 
Hypercholesterolemia  % 31 
Diabetes % 27 
Current Smoking % 33 
Family history of premature CAD  % 31.8 
Prior Beta Blocker use % 31.8 
Prior ACE inhibitor use % 19 
Prior Statin Use % 31 
Prior Clopidogrel use % 7.7 
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Twenty six paired coronary aspirate and femoral arterial sera were assayed for 
both IgG and IgM antivimentin antibody. The median coronary IgG titre was 55 
(38, 65) in contrast to the titre of 70 (61, 77) in the femoral sera (p < 0.0001). 
Similarly the coronary and the femoral titres of IgM antivimentin antibody were 
71(47, 85) and 48 (61, 92) respectively, p= 0.0002 (fig 7.3). 
 
 
Figure 7.3: Coronary and femoral antivimentin antibody titres 
 
7.4 Conclusions 
The coronary aspirate sera demonstrated consistently slightly lower titres of both 
IgG and IgM antivimentin antibodies.   
Although this is interesting, all titres in this study are in the range of those found in 
the peripheral blood of healthy volunteers (50-70). 
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As discussed earlier, cells undergoing apoptosis can express vimentin extra-
cellularly. The lower titres of coronary thromboaspirate antivimentin antibody could 
potentially be caused by sequestration of the antibody by formation of antigen 
antibody complexes on the surface of the endothelial cells, though this remains 
speculative and requires further investigation. 
 
 
110
 CHAPTER 8:  LIQUID PHASE- CYTOTOXICITY AGAINST 
ENDOTHELIAL CELLS 
 
 
8.1. Background 
Derangement in the integrity of endothelial function is a surrogate marker of 
cardiovascular disease and persistent deterioration is predictive of poor clinical 
outcomes.355  Furthermore, among patients presenting with ACS, impaired 
peripheral endothelial function measured during the first 5 days following an index 
event, independently identifies patients at an increased risk of recurrent coronary 
instability.356,357 We aimed to evaluate the effect of the sera obtained from 
atherothrombotic aspirate of patients with ST elevation myocardial infarction on 
healthy endothelial cells (Primary human umbilical vein endothelial cells, 
HUVECS) as a surrogate for potential cytotoxicity against distal vascular 
endothelium beyond the site of coronary occlusion during reperfusion.   
8.2. Methods 
Primary human umbilical vein endothelial cells (HUVECs) were sub-cultured as a 
monolayer on a 24 well plate for 24 hours and the plating confirmed by optical 
microscope. The wells were washed with modified Eagle’s media (Sigma, UK) and 
500 μl of paired sera from coronary aspirate and femoral artery diluted 50 % on 
media was introduced into each well and incubated at 37 °C for 4 hours.  The 
endothelial cells were harvested by trypsinyzing the wells with 250 microlitres of 
trypsin (Sigma, UK). The cells were suspended to a concentration of 100,000/ ml, 
washed, centrifuged at 1500 RPM for 6 minutes, and re-suspended with 100 μl of 
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Binding Buffer (Beckman Coulter). A positive control was obtained by incubating 
the cells with 3% formaldehyde for 30 minutes.   Both the positive control and the 
test samples were subjected to annexin V and Propidium Iodide staining as 
detailed earlier and analysed in the flow cytometer within 30 minutes. 
8.3. Results  
Patient Characterstics:  
 
 
 
 STEMI 
(n=20) 
Age: Mean years.  62 (17) 
Sex (% Male) 75 
Pain to reperfusion time: Minutes(SD) 168 (180) 
Peak Creatinine Kinase U/l(SD)  1500 (1380) 
Peak Troponin I ug/l (SD) 98 (239) 
Total Cholesterol mmol/l (SD) 5.1 (1.4) 
Random Glucose mmol/l (SD) 9 (5) 
Hypertension %  60 
Hypercholesterolemia  % 40 
Diabetes % 30 
Current Smoking % 30 
Family history of premature CAD  % 20 
Prior Beta Blocker use % 20 
Prior ACE inhibitor use % 20 
Prior Statin Use % 40 
Prior Clopidogrel use % 10 
Twenty paired coronary and femoral sera were incubated with the HUVECS: 17 
pairs were incubated for 4 hours and the remaining 3 pairs for 24 hours.  Within 4 
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hours 19 (14, 24) of the HUVECS incubated with the coronary sera underwent 
apoptosis (annexin v positive, propidium iodate negative) in contrast to 8  (17, 4) 
of the HUVECS incubated with the femoral arterial sera, p<0.001. 
 
 
Figure 8.1a Apoptotic cells 
 
 
 
 
Figure 8.1b viable cells 
 
 
 
 
Figure 8.1c dead cells 
 
 
Figure 8.1 Cytotoxicity against endothelial cells 
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There was no difference in the magnitude of viable (annexin v and propidium 
iodate negative; 74(64, 82) versus 77 (70, 84), p=0.48 and dead (doubly positive -
annexin v and propidium iodate positive; 6 (4, 7.5) versus 6.2 (3, 8), p=0.98 
endothelial cells that were incubated with coronary sera and femoral sera 
respectively for 4 hours 
To delineate the temporal change in the degree of apoptosis, in a separate set of 
experiments, the HUVECS were incubated with paired coronary and femoral sera 
for 2 hours, 3 hours, 4 hours and 24 hours consecutively and doubly stained with 
annexin V and propidium iodate (Figure 8.2). As illustrated below, near maximal 
apoptosis (19.2 ) was evident on the HUVECS incubated with the coronary sera. 
In contrast the HUVECS incubated with the femoral sera demonstrated 
progressive increment in apoptosis (9, 12.5 and 16 at 2hours, 3 hours and 4 hours 
respectively. The magnitude of the viable HUVECS did not alter significantly with 
coronary sera (71, 74, and 67) in contrast to the femoral sera (79, 76, and 70).      
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Figure 8.2: Time course of endothelial cell apoptosis 
 
 
At 24 hours  of 12  of the HUVECS incubated with coronary sera were positive for 
annexin v and negative for propidium iodate, in contrast to 6.5  of HUVECS 
incubated with femoral sera. More interestingly, the magnitude of viable 
endothelial cells when incubated with the coronary aspirate was 38  in contrast to 
10 in the femoral sera. 
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Femoral sera @ 24 hours Coronary sera @ 24 hours 
 
                                          
 
 
Figure 8.3: Endothelial cell viability at 24 hours 
 
8.4. Conclusion 
It appeared from this small study that coronary artery sera induced more 
apoptosis on endothelial cells than femoral artery sera. Such an effect could be 
important in the mechanism of myocardial damage following restoration of flow in 
reperfusion of STEMI. This serum toxicity effect may be antibody related, possibly 
due to IgM as suggested by the data from chapter 6. However there remains the 
possibility that these effects are not due to antibody. Further studies need to be 
undertaken including dose-response curves and removal of immunoglobulin from 
patients’ serum.  
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 CHAPTER 9: CONCLUSIONS 
 
9.1. Rationale and plan of investigation 
 
As set out in chapter 1, the primary objective of this thesis was to define the 
involvement of immune cells and the soluble auto-reactive antibodies, contained 
within ex-vivo athero-thrombotic aspirate obtained from the occlusion site of the 
infarct related coronary artery of patients with acute myocardial infarction 
undergoing primary percutaneous angioplasty. The reasons for this were both to 
investigate the pathogenesis of coronary atherothrombosis, and to examine 
possible mechanisms involved in myocardial damage at the restoration of flow in 
STEMI. 
In order to achieve this aim the coronary athero-thrombotic aspirate was first 
filtered to segregate the particulate thrombus. The ex-vivo thrombus was 
sectioned and subjected to immunohistochemistry (Chapter 3).  The filtrate of the 
coronary aspirate, its paired femoral arterial blood and their derivatives (for 
example the platelet rich plasma) were stained with monoclonal antibodies for 
multicolour flow cytometry. Detailed T cell subset phenotypic analysis was 
undertaken (Chapter 5). Similarly the sera from both the sites were assayed for 
reactive antibodies and assessment of cytoxicity (Chapter 6 + 8).  By necessity the 
investigations in this thesis were global in terms of both thrombus composition and 
detailed analysis of many cell types in the thromboaspirate. This was necessary 
because of the paucity of available data. However this work will lay down the basis 
for more focussed subsequent studies upon the specific findings. 
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9.2. Specific findings of the investigations 
9.2.1. General 
Although the adaptive immune system may contribute to the plaque instability and 
initiation of acute coronary syndrome, T-lymphocytes were not observed in 
significant amounts within the architecture of intracoronary thrombus, (chapter 3), 
since immunohistochemistry of the ex-vivo thrombus failed to demonstrate 
lymphocytes in any significant number, although they comprise about 30% of the 
circulating blood cells.  However, the innate immune cells including monocytes 
and granulocytes seemed to be an integral part of the thrombus and they 
expressed ligand (CD11b) for the fibrin polymer. In our preliminary 
thermoelastography experiments, in which in-vitro clots were generated in the 
presence of inhibiting monoclonal antibody against CD11b, the antibody reduced 
the tensile strength of the thrombus (Data not included in the Thesis).   Since this 
thesis planned to address principally the adaptive immune system, and very few 
lymphocytes were seen in the thrombus, the plan of investigation focussed 
principally on the resident lymphocytes (chapter 5), Immmunoreactive antibodies 
(chapters 6 and 7) and the cytotoxic potential of coronary serum (chapter 8) . 
9.2.2. Platelet activation 
Platelet activation occurs in acute coronary syndromes, however, only 
approximately 1/5th of the platelets in the coronary aspirate of patients with ST 
elevation myocardial infarction expressed the conventional activation marker P-
selectin on their surface (chapter 4). The occurrence of the index thrombotic event 
in acute ST elevation myocardial infarction is temporally heterogeneous, with 
more than 50% patients harbouring old thrombus.358,359 The expression kinetics of 
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inducible markers of platelet activation are variable:  The P-selectin expression is 
rather transient and probably explains why the observed CD62P expression in the 
coronary aspirate is not significantly different than in the peripheral circulation. 
Conversely, CD40L has longer expression kinetics and this may explain the 
differential expression between the coronary aspirate and the femoral artery.  
Similarly PAI-1 and vimentin may also be more reliable markers of platelet 
activation. Using novel markers of platelet activation with different expression 
kinetics like CD40L, PAI-1 and vimentin it may be possible to obtain incremental 
information regarding the degree of platelet activation. Due to the absence of 
robust and validated assays to determine the degree of in-vivo activation of 
platelets, patients with acute coronary syndromes are empirically treated with 
multiple antiplatelet and antithrombotic therapies. Although this approach has 
improved the prognosis, it has also significantly augmented haemorrhagic risks.  It 
needs to be evaluated whether these novel platelets activation markers can be 
used as predictors of risk and assist in tailoring antiplatelet therapies. 
9.2.3. Platelet-Leukocyte conjugates 
Activation of platelets enhances the heterotypic interaction between platelet-
monocytes and platelet-granulocyte. Therefore, platelet-monocytes and platelet-
granulocyte conjugates can be considered a surrogate marker of platelet 
activation. As anticipated platelet-monocyte and platelet-granulocyte conjugates 
were greatly enhanced in the coronary aspirate compared to femoral blood in 
patients with acute myocardial infarction (Chapter 4). Since platelets facilitate the 
transmigration of leukocytes across the endothelium, platelet leukocyte co-
aggregation at the site of coronary occlusion could potentially enhance the 
 
 
119
delivery of leukocytes to the infarcted myocardium. Whether this effect is 
pathogenic and contributes to ischemia reperfusion injury is unknown. 
We also observed an increase in lymphocyte platelet conjugates in the coronary 
aspirate (chapter 4). The kinetics of heterotypic interaction between lymphocyte 
and platelet is slower than that of monocyte and granulocyte-platelet interaction, 
thus the degree of lymphocyte-platelet co-aggregation may also depend on the 
duration for which coronary artery had remained occluded. A correlation between 
the pain to reperfusion time and the percent of lymphocyte-platelet conjugates 
showed the presence of a weak but statistically significant association. Since pain 
to reperfusion times in one of the major determinants of outcome after acute 
myocardial infarction, the lymphocyte-platelet conjugate may also predict 
outcomes. However, a large outcome based clinical research would be required to 
clarify this.  
Previous studies have suggested that activation of lymphocytes and not platelets 
per se increases in vitro conjugate formation between lymphocyte and platelet. 
Thus, the enhanced lymphocyte-platelet conjugates in the coronary aspirate may 
be indicative of increased lymphocyte activation on the coronary aspirate. We 
corroborated this hypothesis by assessing the activation of T lymphocytes using 
CD40L as marker of antigen specific T cell activation and HLA-DR as marker of 
non-specific T cell activation (chapter 5) we found that the lymphocytes from 
coronary aspirate had enhanced expression of the activation markers when 
compared to the circulating T lymphocytes from the femoral artery.    
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9.2.4. T-Lymphocytes 
CD4+ T lymphocytes are the dominant proatherogenic cell population amongst the 
T lymphocytes, of which CD4+CD28null T cells are of special interest due to their 
proinflammatory cytotoxic potential despite having a helper T cell phenotype. We 
evaluated the degree of loss of co-stimulatory molecule CD28 on the CD4 T cell 
population across the spectrum of the coronary disease (chapter 5) and observed 
that in ST elevation myocardial infarction there were more CD4+ T cells of CD28null 
phenotype in the coronary aspirate when compared to the circulating CD4+ T cells 
in the femoral artery.   
In vitro studies have suggested these cell populations exert a cytolytic effect 
against endothelial cells. However, cloned and activated cell lines of the 
CD4+CD28null cells were used in the experiments. In vitro cloning and activation 
could have altered the properties of the cells and the results may not be directly 
applicable to in vi-vivo situation. So, based upon our findings, further experiments 
assessing the cytoxicity against endothelial cells by primary CD4+CD28null cells 
isolated from the coronary artery of patients with STEMI, may provide more 
relevant mechanistic insight.  
We observed relative concentration of CD4+CD28null cells at the culprit site of the 
occluded coronary artery of patients with STEMI, and these cells may be released 
downstream in to the distal microvascular bed during reperfusion. It is possible 
that they may contribute to reperfusion injury. 
Chronic antigenic stimulation of the CD4+ T cells is one of the proposed 
mechanisms of generation of the CD4+CD28null T cells. Thus one would expect the 
CD4+CD28null T cells to have memory T cell phenotype (CD45RO+).  Interestingly, 
CD4+CD28null T cells in the coronary aspirate less frequently expressed the 
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CD45RO than the circulating CD4+CD28null T cells in the femoral artery. This 
suggests that whilst exposure to antigen frequently contributes to loss of CD28 in 
the CD4+ T cells in the peripheral circulation, a different mechanism may exist at 
the site of coronary occlusion. Research in the cytokine and mRNA profile of 
CD4+CD28null T cells obtained from the coronary aspirate and femoral artery may 
clarify this.  
 Of the memory CD4+CD28null T cells, the cells from the coronary aspirate more 
frequently expressed the effector memory T cells phenotype (CCR7-) in contrast to 
the central memory phenotype (CCR7+) of the peripheral blood memory 
CD4+CD28null T cells. This may indicate that the CD4+CD28null T cells obtained 
from the coronary aspirate originate from the ruptured plaque.  
Although amplification of the pro-atherogenic cells may be important in the 
progression of atherosclerotic diseases, the attenuation of immune modulating 
cells may also be important. Indeed, in patients with ST elevation myocardial 
infarction, the immune regulatory CD4+ T cells (Tregs) that expressed the nuclear 
transcription factor FoxP3 were present in reduced number on the coronary 
aspirate when compared to the peripheral circulation (chapter 5). Profiling the 
titres of the cytokines IL-10 and TGF-β on the coronary aspirate and the femoral 
artery may increase the robustness of this finding.  
9.2.5. Immunoreactive IgM non-HLA antibodies 
Significantly more auto-reactive IgM non-HLA antibodies were present in the 
coronary aspirate sera compared to the femoral sera (chapter 6). This could 
potentially induce higher degree of cellular apoptosis of the leukocytes in 
presence of complement. Pentameric IgM antibodies can avidly fix and activate 
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the classical pathway of complement system to produce the membrane attack 
complex. Since complement is known to be deposited on the surface of blood 
vessels and myocardium after myocardial infarction, the presence of IgM could be 
mechanistically important in the pathogenesis of acute coronary syndromes, and 
the aetiology of myocyte damage following the restoration of flow in STEMI.  
9.2.6. Antivimentin antibodies 
Our group has a special interest in vimentin, and since it was not practical to study 
vimentin directly, we sought antivimentin antibody evidence. Interestingly sera 
from the coronary aspirate contained less of both IgG and IgM antivimentin 
antibodies (chapter 7). This was an unexpected finding. Although vimentin is an 
intracellular intermediate filament, it is known to be expressed extracellularly in 
response to activation, stress and apoptosis.  Since the endothelial cells of the 
infarct related artery are stressed and apoptotic they may have extracellular 
expression of vimentin. This may sequestrate the antivimentin antibody thus 
reducing the titre of the antivimentin antibody in the coronary sera.    
9.2.7. Serum cytotoxicity 
The coronary sera induced more apoptosis than the femoral artery sera when 
incubated with the HUVECS.  Whilst the identifying the specific humoral factor or 
factors responsible for this was beyond the scope of the work of this thesis, this 
ability to induce apoptosis may be important in the aetiology of myocyte damage 
following the restoration of flow in STEMI.  
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9.3. Study Limitations 
      9.3.1. Sample size:  
Although 62 patients with ST elevation myocardial infarction undergoing primary 
angioplasty were recruited in to this study, most of the experiments were 
performed in twenty patients. This magnitude of sample size is underpowered for 
assessment of clinical outcomes, so no clinical conclusions are drawn from this 
mechanistic series of studies. 
9.3.2. Dilutional effect:  
During aspiration of the coronary athero-thrombotic material some blood upstream 
of the occlusion site is often aspirated, though the intention of the operator in the 
therapeutic procedure is to remove primarily the thromboaspirate form the site of 
the occlusion. Since the blood proximal to the occlusion site is likely similar to the 
femoral artery this would reduce the gradient of difference between coronary 
aspirate and femoral blood, suggesting that the differences we observed may be 
under- rather than over-estimates.    
9.3.3. Aspirin and heparin effect: 
 Patients admitted to our hospital with suspected ST elevation myocardial 
infarction invariably received aspirin therapy during their transport to the hospital. 
Furthermore the coronary aspiration thrombectomy was performed after 
anticoagulation with heparin.  The changes we observed were therefore in the 
presence of aspirin and heparin. 
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9.3.4. Sampling Issues: 
 Due to the basic methodology of aspiration thrombectomy there is loss of spatial 
orientation and fragmentation of the aspirated thrombus limiting any ‘polarity’ 
inferences from the clot architecture such as the ‘head and ‘tail’.   
9.3.5 Cytotoxicity assays 
Studies investigating cytotoxicity were limited for a number of reasons in these 
exploratory assays: 
1. In all cases small amounts of cytotoxicity were detected (maximum 20%). 
These studies did not use patient derived target cells which may be more 
sensitive. Further studies should include cytokine treatments of target cells to 
measure their sensitivity. 
2. Full dose dependency assays were not performed. 
3. Immunoglobulin should be removed from sera to confirm the toxic effects are 
immunoglobulin induced. 
4. The study group was small. 
9.4. Future directions 
The exploratory work of this thesis explored a number of new areas and raises a 
number of key questions surrounding the involvement of the adaptive immune 
system in acute coronary syndromes at the site of coronary occlusion. Two key 
areas that the group is taking forward at present are: 
9.4.1 CD24+28null cell clonality 
Further investigation into CD24+28null cell typing may be valuable from the 
perspective of gaining insight into atherogenesis:  It is possible that the effector 
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memory phenotype cells we observed at higher concentration in the coronary than 
the femoral artery may have originated from the ruptured atherosclerotic plaque. 
We aim therefore to define the clonality of these T-cells defined by receptor 
mRNA. If they are clonal, then a search for the common antigen concerned may 
help understand the pathogenesis of plaque development. 
9.4.2 Coronary serum proteomics 
Understanding which components of the coronary filtrate serum are causing 
cytotoxicity may be therapeutically important. Reperfusion injury on restoring flow 
to an occluded infarct related coronary artery is a well recognised clinical problem 
with significant morbidity and mortality, and based upon our findings, it is possible 
that humoral factors released downstream during reperfusion therapy may be 
important in this regard. We plan to perform a detailed proteomic analysis on 
coronary thromboaspirate filtrate serum to search for candidate proteins. If we can 
demonstrate high concentrations of proteins potentially implicated in the 
reperfusion injury phenomenon then this may give us the opportunity to work 
towards the development of potential strategies to reduce the clinical burden of 
this problem. 
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